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ABSTRACT 
West Nile virus (WNV) is a neurotropic flavivirus that is maintained in an enzootic cycle 
between mosquitoes and birds, but can also infect and cause disease in humans and other 
vertebrate species. Most of WNV infections in humans are asymptomatic, but approximately 
20% of infected people develop clinical symptoms, although severe neurological diseases 
are observed in less than 1% of them. WNV is the most widely distributed arbovirus in the 
world and has been recently associated with outbreaks of meningo-encephalitis in Europe, 
including Italy, caused by different viral strains belonging to distinct lineages 1 and 2. The 
hypothesis is that genetic divergence among viral strains currently circulating in Italy might 
reflect on their pathogenic potential and that the rapid spread of WNV with increased 
pathogenicity within naïve population suggest that epidemic forms of the virus may encode 
mechanisms to evade host immunity. Infection with WNV triggers a delayed host response 
that includes a delay in the production of interferon-α (IFN-α). IFNs are a family of 
immuno-modulatory cytokines that are produced in response to virus infection and serve as 
integral signal initiators of host intracellular defenses. The increased number of human cases 
and the lack of data about virulence of European WNV isolates highlight the importance to 
achieve a better knowledge on this emerging viral infection. In the present study, we 
investigate the phenotypic and IFN-α-regulatory properties of different WNV lineage 1 and 
2 strains that are circulating in Europe/Italy in two cell lines: Vero and 1321N1. We 
demonstrate that: Vero and 1321N1 cells are capable of supporting WNV replication where 
different WNV strains show similar growth kinetics; WNV lineage 2 strain replicated in 
Vero and 1321N1 cells as efficiently as WNV lineage 1 strains; and both lineages 1 and 2 
were highly susceptible to the antiviral actions of IFN-α.  
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INTRODUCTION 
1. INTRODUCTION TO THE ARBOVIRUSES 
The term arbovirus is an acronym for arthropod-borne virus (Hubalek et al., 2014). It 
has no taxonomic significance but rather is an ecologic term used to define viruses that 
require hematophagous (blood feeding) arthropod vectors such as mosquitoes and other 
biting flies, and ticks for transmission between hosts (WHO, 1985; Gubler DJ., 2001; 
Weaver SC. and Reisen WK., 2010).  
Being, by definition, biologically transmitted, arboviruses must replicate in the arthropod 
vector prior to transmission, as opposed to being mechanically transmitted, without 
replication in the vector, through contaminated mouthparts (Weaver SC., 1997; Weaver 
SC. and Reisen WK., 2010). Biological transmission can be vertical, involving the 
passage of the virus from an infected female vector to both male and female offspring. 
Horizontal transmission can be venereal, from a vertically infected male directly to a 
female vector, as well as oral from a female vector to a vertebrate host via the saliva 
during blood feeding. The latter horizontal mode of transmission is most common for the 
majority tract following a viremic bloodmeal, dissemination of the virus in the vector, 
and eventual virus replication in the salivary glands, followed by the injections saliva 
during blood feeding (Weaver SC. and Reisen WK., 2010). Thus, in general arboviruses 
require a minimum of two hosts to complete their life cycle: a vertebrate and an 
arthropod (WHO 1985; Gubler DJ., 2002). For most arboviruses (e. g. Usutu virus, West 
Nile virus, Japanese encephalitis virus) humans are often dead-end hosts, as they do not 
develop the high viremias needed to infect the arthropod vectors (Filipe A., et al., 1985; 
Dobler G., 1996; Gubler DJ., 2001; Jones KE., et al., 2008; Cleton N., et al., 2012). 
Therefore, humans are not necessary for virus maintenance and they represent just an 
accident during the biological transmission among vectors and hosts (Diaz LA. et al., 
2013). Only a few viruses like Yellow fever, Chikungunya and Dengue virus have 
expanded their host range to include humans as an amplifying host (Cleton N., et al., 
2012). 
There are currently at least 530 viruses registered in the International Catalogue of 
Arboviruses: about 40% are known or probable arboviruses; another 54% are listed as 
possible arboviruses and about 6% are listed as definitely or probably not arboviruses 
(Fig. 1) (Karabatson N., 1985; Gubler DJ., 2002; Lequime S. and Lambrechts L., 2014). 
Most of the viruses listed in this catalogue are zoonoses or viruses that have vertebrate 
animals other than humans as their principal reservoir hosts (Gubler DJ., 2001) and of 
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the over 530 suspected arbovirus species more than 150 are documented to cause disease 
in humans (Karabatson N., 1985; Cleton N., et al., 2012; Lequime and Lambrechts, 
2014). For most arboviruses (e. g. Usutu virus, West Nile virus, Japanese encephalitis 
virus) humans are often dead-end hosts, as they do not develop the high viremias needed 
to infect the arthropod vectors (Filipe A., et al., 1985; Dobler G., 1996; Gubler DJ., 
2001; Jones KE., et al., 2008; Cleton N., et al., 2012). Therefore, humans are not 
necessary for virus maintenance and they represent just an accident during the biological 
transmission among vectors and hosts (Diaz LA. et al., 2013). Only a few viruses like 
Yellow fever, Chikungunya and Dengue virus have expanded their host range to include 
humans as an amplifying host (Cleton N., et al., 2012). 
Arboviruses are included in different taxonomic families, the majority belonging to the 
Flaviviridae, Bunyaviridae or Togaviridae families, but a small number are member of 
the Rhabdoviridae, Reoviridae, and Orthomyxoviridae families (Fig. 2) (Dobler G., 
1996; Claton N., et al., 2012; Go YY., 2014). Among them, four major viral genera 
account for the majority of arboviral disease: Flavivirus (e. g., Dengue, West Nile, 
Japanese encephalitis, and Yellow fever viruses), Alphavirus (e. g., Chikungunya, 
Eastern equine encephalomyelitis, Western equine encephalomyelitis and Venezuelan 
equine encephalitis viruses), Orthobunyavirus (e. g., California encephalitis and 
LaCrosse viruses) and Phlebovirus (e. g., Rift Valley fever and Sandfly fever viruses) 
(Lequime and Lambrechts, 2014). 
 
 !
Figure 1: Arboviral status of viruses registered in the arbovirus catalogue (Gubler 
DJ., 2001).  
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Figure 2: Classification of arboviruses. Arboviruses are included in six different 
taxonomic virus families. a) Arboviruses that cause human encephalitides belong to four 
genera in four virus families (Go YY., et al., 2014). 
 
Arboviruses as a group have a worldwide distribution and that of each arbovirus is 
restricted by the ecological parameters governing its transmission cycle (Gubler DJ., 
2001; Gubler DJ., 2002). The majority of them were first isolated in tropical areas such 
as Africa, South America and in some Asian countries where climate conditions permit 
year-round transmission by cold-blooded arthropods (Karabatsos N., 1985; Gubler DJ., 
1996; Gubler DJ. and Roehrig JT., 1998; Go YY., et al., 2014). However, the geographic 
distribution and frequency of epidemic outbreaks of arboviral diseases have expanded 
dramatically across the world in the past several decades and they are responsible for 
significant global public health problems (Gubler DJ., 1996; Gubler DJ., 2001). In 
general, several factors such as environmental disturbs from anthropogenic activities 
(Vasconcelos P. et al., 2001), climatic changes affecting vector and host population 
fluctuations (Weaver SC. and Reisen WK., 2010), human movements through airplanes, 
animal trade and migration (Pfetter M. and Dobler G., 2010), and changes in viral 
genetics (Go YY., et al., 2014) facilitated expansion and transmission of arboviruses 
resulting in emergence/reemergence of arboviral disease outbreaks in new regions in the 
world (Diaz LA., et al., 2013). Introduction of West Nile virus (WNV) into the New 
World and the emergence of Japanes encephalitis virus (JEV) in Australia are few 
prominent examples of recent unexpected emerging/reemerging zoonotic disease (Hanna 
JN., et al., 1996; Hanna JN., et al., 1999; Go YY., et al., 2014). 
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2. FLAVIVIRUS 
Flaviviruses are a group of arboviruses belonging to the family Flaviviridae (Pastorino 
B., et al., 2010). The genus Flavivirus consists of more than 70 positive-sense single-
stranded RNA viruses (Tyler S., et al., 2011). Several members of this genus are the 
most clinically important arboviruses world-wide, that cause serious human and animal 
disease and constitute major international health problems. These include West Nile 
virus (WNV), Dengue virus (DENV), Japanese encephalitis virus (JEV), Yellow fever 
virus (YFV), tick-born encephalitis virus (TBEV), Murray Valley encephalitis virus 
(MVEV), and St. Louis encephalitis virus (SLEV) (Tab. 1) ( Mackenzie JS., et al., 2004; 
Gubler DJ., et al., 2007; Gould EA. and Solomon T., 2008; Cleton N., et al., 2012) and 
they are transmitted by mosquitoes (DENV, YFV, JEV, WNV) or ticks (TBEV) (Kuno 
G., et al., 1998; Gaunt MW. et al., 2001).  
The Flaviviruses can be grouped by pathogenicity, geographic distribution, antigenic 
complex and subcomplexes based on classic serological criteria or into clusters, clades, 
and species, according to molecular phylogenetics (Calisher CH. and Gould EA., 2003; 
Lindenbach BD., et al., 2007; Ye J., et al., 2013). Generally, they can be divided in 
three distinct groups: mosquito-borne viruses, tick-borne viruses, and viruses with 
unknown vectors (Cook S., et al., 2012). Mosquito-borne viruses infect a variety of 
animal species and humans. They can be further subdivided into Culex and Aedes 
clades, which also differ in their vertebrate hosts and pathogenesis. Culex-clade viruses 
have bird reservoirs, are neurotropic, and frequently cause meningo-encephalitis, while 
Aedes-clade viruses have primate reservoirs, are non-neurotropic, and mainly result in 
hemorrhagic diseases (Solomon T., et al., 2000; Gaunt MW., et al., 2001; Beck C., et 
al., 2013). The tick-borne viruses also form two groups: one group circulates among 
seabirds, while the other, the tick-borne encephalitis group, is primarily associated with 
rodents. This latter group generally produces encephalitic disease, although Omsk 
Hemorrhagic Fever virus (OHFV) and Kyasanur Forest Disease virus (KFDV) also 
cause hemorrhagic deseases in humans (Beck C., et al., 2013). The mosquito-borne and 
tick-borne groups, although distinct, appear to have evolved via a common ancestral line 
that diverged from nonvector borne viruses (i.e., for which no arthropod vectors are 
known) (Lindenbach BD., et al., 2007). Moreover, tick-borne flaviviruses seems to 
evolve at slower rate than mosquito-borne flaviviruses, probably as a results of a slower 
virus replication rate in tick and longer generation times of their tick hosts (Gould EA., 
et al., 1997).  The salient features of Flavivirus taxonomy are illustrated in Figure 3.  
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Because of their evolution and epidemiology is largely determined by ecological needs 
of their invertebrate and vertebrate hosts (Fig. 3), Flaviviruses have distinct 
geographical distributions. The viruses have evolved to use whichever animal host and 
insect vector are present in a particular area. In general, mosquito-borne viruses tend to 
occur in warm climates, whereas the tick-borne viruses are more important in cooler 
climates (Solomon T., and Mallewa M., 2001). For example, YFV is endemic in tropical 
and subtropical regions in Africa and South-America and the endemic regions of 
DENV, geographically, overlap with those of YFV in Africa and South-America. 
However, DENV extends not only to Middle America and southern parts of North 
America but also to large parts of South-East Asia, where YFV is not found (Vasilakis 
N., et al., 2011). In Europe, many Flaviviruses are endemic (West Nile, Usutu, tick-
borne encephalitis viruses) or occasionally imported (dengue, yellow fever viruses) 
(Beck C., et al., 2013). 
 
 
 
Table 1: Medically important Flaviviruses (Solomon T. and Mallewa M., 2001). 
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Figure 3: Phylogenetic tree showing the association of the groups of related viruses 
with their invertebrate vectors, vertebrate hosts, and geographic distribution.  
ALF=Alfuy. MVE=Murray Valley encephalitis. JE=Japanese encephalitis. USU=Usutu. KOU=Koutango. 
KUN=Kunjin.WN=West Nile. YAO=Yaounde. CPC=Cacipacore. ARO=Aroa. IGU=Iguape. NJL=Naranjal. 
KOK=Kokobera. STR=Stratford. BAG=Bagaza. IT=Israel Turkey meningoencephalomyelitis virus. 
TMU=Tembusu. THCAr=strain of Tembusu. ILH=Ilheus. ROC=Rocio. SLE=St Louis encephalitis. 
DEN=dengue. SPO=Spondweni. ZIK=Zika forest. KED=Kedougou. UGS=Uganda S. JUG=Jugra. 
POT=Potiskum. SAB=Saboya. BOU=Bouboui. EH=Edge Hill. YF=yellow fever. SEP=Sepik. EB=Entebbe 
bat. SOK=Sokoluk. YOK=Yokose. GGY=Gadgets Gully. KFD=Kyasanur Forest disease. LGT=Langat. 
LI=Louping ill. NEG=Negishi. Sof=Sofj in. FETBE=far eastern TBE. Vs=Vasilchenko. OHF=Omsk 
haemorrhage fever. KSI=Karshi. RF=Royal Farm. POW=Powassan. KAD=Kadam. MEA=Meaban. 
SRE=Saumarez Reef. TYU=Tyuleniy. APOI=Apoi. BC=Batu Cave. PPB=Phnom Penh bat. CI=Carey Island. 
BB=Bukalasa bat. DB=Dakar bat. RB=Rio Bravo. MML=Montana myotis leucoencephalitis. CR=Cowbone 
Ridge. MOD=Modoc. SV=Sal Vieja. JUT=Jutiapa. SP=San Perlita. TBE=tick-borne encephalitis. 
WTBE=Western European TBE. RSSE=Russian spring and summer encephalitis. NKV refers to viruses with 
no known vector (Gould EA and Solomon T., 2008). 
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3. WEST NILE VIRUS 
West Nile virus (WNV) is a mosquito-borne neurotropic pathogen, enveloped positive-
strand RNA virus that belongs to the family Flaviviridae, genus Flavivirus (Andreson et al., 
1999; Lanciotti et al., 1999; Cho H. and Diamond MS., 2012; Qian F., et al., 2014). Within 
the genus Flavivirus, WNV has been serologically classified within the Japanese encephalitis 
(JEV) antigenic complex, which includes the human pathogens JEV, Murray Valley 
encephalitis (MVE), St Louis encephalitis (SLE), and Kunjin (KUN) viruses. WNV is 
maintained in a mosquitoes-bird-mosquito transmission cycle (Work TH., et al., 1955), 
whereas humans and horses are considered dead-end hosts (De Filette M., et al., 2012). 
WNV is endemic in parts of Africa, Europe, the Middle East, and Asia (Dauphin G., et al., 
2004), and since 1999 has spread to North America, Mexico, South America, and the 
Caribbean (Lim SM., et al., 2011).  
The WNV has been reported in dead or dying birds of at least 326 species (CDC Database). 
In birds, the clinical outcome of infection is variable: some species are resistant to disease, 
while others are particularly susceptible (De Filette M., et al., 2012). 
In humans, WNV was first isolated in 1937 from the blood of a woman with an undiagnosed 
febrile illness in the West Nile district of northern Uganda (Smithburn KC., et al., 1940). It 
was not observed again until the 1950s, when WNV was shown to be widespread in the 
Middle East and India and caused outbreaks of human disease in Israel. Moreover, sporadic 
epidemics were reported in southern France and Russia in the early 1960’s and in South 
Africa, Belarus, and Ukraine in the 1970’s. However, until the mid-1990’s, WNV was rarely 
seen and was considered as a minor importance to public health because it only appeared 
sporadically (Karabatsos N., 1985; Hayes C., 1989; Gubler DJ., 2002; De Filette M. et al., 
2012). In the 1990’s, the epidemiology of infection apparently changed. Epizootic and 
epidemics of severe neurologic disease in horses, birds, and humans began to occur with 
increasing frequency and severity compared to previous outbreaks (Hubalek Z. and 
Halouzka J., 1999). The first human cases of WNV in its lethal encephalitis form were 
reported in Algeria in 1994. In 1996 severe outbreaks with a high incidence of neurological 
disease and death were reported in Marocco, Tunisia, Italy, Russia, Israel and France (Zeller 
HG. and Schuffenecker I., 2004). In the late 1990’s, the virus became more virulent and 
expanded its geographical range to the Western Hemisphere (Rossi SL. et al., 2010). Since 
its first incursion in New York city, in the 1999 (Hayes CG., 2001), it has rapidly spread 
throughout the continental United States where it has been estimated to cause more than 4 
million infections, resulting in over 780.000 illnesses, 38.000 clinically confirmed cases, and 
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1.600 deaths between 1999 and 2014 (Petersen LR., et al., 2012; CDC 2013; Suthar MS. and 
Pulendran B., 2014) becoming a major public health in many parts of the world and 
veterinary concern (De Filette M. et al., 2012).  
In humans, the clinical manifestations range from asymptomatic (approximately 80% of 
infections) to meningo-encephalitis/paralysis and death (less than 1% of infections) (Hayes 
EB. and Gubler DJ., 2006; Rossi SL., et al., 2010; Brandler S. and Tangy F., 2013). Despite 
the ongoing risk to public health, there are still no specific therapy or vaccine approved for 
use against WNV infection in humans (Lim SM., et al., 2011; Cho H. and Diamond MS., 
2012). 
 
3.1 STRUCTURE OF WNV 
The structure of WNV particles, specifically New York 99, the strain responsible for the 
outbreak in the United States, have been elucidated by Mukhopadhay et al. in 2003 (Fig. 4) 
(Mukhopadhay S. et al., 2003; Kaufmann B., et al., 2010). Electron microscopy and image 
reconstruction techniques established that mature WNV virion is a small spherical 
icosahedral with a 50 nm diameter, with no surface projections or spikes. The outermost 
layer contains the highest density and corresponds to the viral envelope (E) and membrane 
(M) transmembrane proteins that are embedded in a lipid bilayer forming the envelope of the 
virion (Adams SC., et al., 1995; Berthet FX., et al., 1997; Mukhopadhay S. et al., 2003; 
Kramer LD., et al., 2007; Kramer LD., et al., 2007; Rossi SL., et al., 2010; Colpitts TM., et 
al., 2012; De Filette M., et al., 2012). This outer shell is constituted by 180 copies of M 
protein and an equal number of copies of the E glycoprotein disposed as 90 anti-parallel 
homodimers arranged in three distinct symmetry environments, thus resulting in a particle of 
icosahedral symmetry (Mukhopadhay S. et al., 2003; Kaufmann B., et al., 2010). Inside the 
envelope is the nucleocapsid core, which contains multiple copies of the capsid (C) protein 
and the genome RNA (Kramer LD., et al., 2007). The C proteins, located inside virions, 
have no discernible nucleocapsid symmetry and no contacts between C proteins and either E 
or M on the inner side of the virion envelope have been observed (Zhang W., et al., 2003). 
Although nucleocapsid particles consisting of multiple copies of the C protein and genome 
RNA are observed after removal of the virion envelop with nonionic detergent, capsid 
dimers can be dissociated from these structures by treatment with high salt (Kiermayr S., et 
al., 2004). C protein dimers have a very high charge, with half of the basic residues located 
on the face and conserved hydrophobic region that forms an apolar surface on the opposite 
face (Ma L., et al., 2004). It is thought that the apolar surface of the C dimer interacts with 
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the inner side of the virion envelop while the basic residue surface of the capsid dimer 
interacts with the genomic RNA (Brinton MA., 2014).  
 
 
 
 
 
 
 
 
 
Figure 4: West Nile virion. The virus structure as reconstructed by cryo-electron 
microscopy. One asymmetric unit of the icosahedron is indicated by the triangle on the 
surface shaded view. The central section of the reconstruction shows the concentric layers of 
mass density. Reproduced with permission from the American Association for the 
Advancement of Science. (Mukhopadhyay S., et al., 2003; Kramer LD., et al., 2007).  
 
3.2 GENOME OF WNV 
The WNV genome is linear and is constituted by a single-stranded RNA molecule of 
positive polarity (Fig. 5). This RNA molecule of approximately 11.000 nucleotides (nts) in 
length, encodes a polyprotein in a single open reading frame (ORF) that is flanked by 5’ and 
3’ untranslated regions (UTR). These form extensive secondary structures, which are 
important for replication, transcription, translation, and packaging (Shi PY., et al., 1996; 
Khromykh AA., et al., 2001; Friebe P. and Harris E., 2010; Martin-Acebes MA. and Saiz 
JC., 2012). The 5’ UTR of the WNV genome is 96 nts in length, while the length of the 3’ 
UTR varies from 337 to 649 nts. The 5’ end contains a type 1 cap structure (m7GpppAmp) 
that is added by NS5 during genome transcription (Brinton MA., 2014). The variable region 
of the 3’UTR is located just 3’ of the coding region stop codon (Beasly DW., et al., 2001). 
The 3’ end of the genome RNA does not contain a poly A tract but instead terminates with a 
conserved CUOH (Rice CM., et al., 1985; Brinton MA., et al., 1986; Wengler G., et al., 
1991). Proper methylations of the cap structure at guanine N-7 and ribose 2’-OH positions of 
the first transcribed adenine are necessary for optimal infectivity of WNV RNA. Viruses 
defective in the N7 methylation mechanism are non-replicative, and recently the 2’-OH 
! 11!
methylation has been related to evasion of innate immunity by evading certain components 
of interferon response, therefore WNV defective in this methylation mechanism can 
replicate but is attenuated in vivo (Dong H., et al., 2008; Daffis S., et al., 2010).  
The single open reading frame (ORF) of 10.301 nts in most WNV isolated, is translated as a 
single polyprotein of approximately 3000 amino acids that is post- and co-translationally 
cleaved by cellular and viral proteases into ten proteins: three structural proteins (C, 
premembrane or membrane, and envelope) and seven non-structural proteins (NS1, NS2A, 
NS2B, NS3, NS4A, and NS5) (Fig. 5). The three viral structural proteins are encoded within 
the 5’ portion of the ORF and are mainly involved in viral particle formation, whereas non-
structural proteins are encoded within the 3’ portion and their function consists in viral 
replication, virion assembly, and evasion of host innate response (Kramer LD., et al., 2007; 
Lindenbach BD., et al., 2007; Rossi SL., et al., 2010; Brinton MA., et al., 2014). The viral 
polyprotein contains multiple transmembrane domains that determine whether individual 
mature viral proteins are located on the cytoplasmic or luminal side of the endoplasmic 
reticular (ER) membrane after cleavage from the polyprotein (Lindenbach BD., et al., 2013). 
The C, NS3 and NS5 proteins are located on the cytoplasmic side while the PrM, E, and NS1 
proteins are in the lumen and, with the exception of short regions between transmembrane 
domains, the NS2A, NS2B, NS4A and NS4B proteins are located within the ER membrane 
bilayer (Lindenbach BD., et al., 2013; Brinton MA., et al., 2014). 
 
 
 !
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic of WNV genome. A representation of the WNV genome including the 
3 structural proteins that make up virion particle and the 7 non-structural proteins necessary 
for virus replication and immune evasion (Rossi SL., et al., 2010). 
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3.2.1 VIRAL STRUCTURAL PROTEINS 
Capsid (C): The capsid, or core, (C) protein is a highly basic protein of ≈11 kd that contains 
a large number of scattered charged amino acids (Dokland T., et al., 2004; Lindenbach BD., 
et al., 2007) and is implicated in viral assembly and replication (Schrauf S., et al., 2009).   
The N- and C-termini parts of the protein are intrinsically disordered regions and may play a 
role in RNA folding during viral replication by conferring RNA chaperoning activity to the 
C protein (Ivanyi-Nagy R., et al., 2008). The central part of the C protein is a hydrophobic 
region that mediates membrane association (Ma L., et al., 2004; Lindenbach BD., et al., 
2007). Nascent C (anchC) also contains a C-terminal hydrophobic anchor that serves as a 
signal peptide for ER translocation of prM. This hydrophobic domain is cleaved from mature 
C by the viral serine protease (Lobigs M. and Lee E., 1993). The protein dimerizes and 
tetramerizes to build the nucleocapsid that, together with viral RNA, forms the electron-
dense core of the virion that is enveloped by the lipid bilayer. In WNV-infected cells, capsid 
protein can be detected in the cytoplasm, nuclei and the nucleolus of the cell, and it has been 
related to the induction of apoptosis (Yang MR., et al., 2008). Nuclear location of the C 
protein is mediated by a bipartite nuclear location signal and requires specific interaction 
with cellular importins (Bhuvanakantham R., et al., 2009). The capsid protein also interacts 
with other cellular factors, as the inhibitor of the serine/threonine phosphatase PP2A, I (2) 
(PP2A), Hsp70 and Jab1 (Oh WK. and Song J., 2006; Oh WK., et al., 2006; Hunt TA., et al., 
2007). The phosphorilation status of the protein and Jab1 can regulate nuclear location and 
RNA binding activity (Oh WK., et al., 2006; Cheong YK. and Ng ML., 2011; 
Bhuvanakantham R., et al., 2010). The C protein has been also implicated in degradation of 
claudin proteins and disruption of epithelia barrier, thus helping to virus dissemination 
(Medigeshi GR., et al., 2009; Martin-Acebes MA., et al., 2012). 
prM/M: The prM/M is a short transmembrane glycosylated protein associated to the lipid 
bilayer of the virion. The glycoprotein precursor of M protein, prM (≈26 kd), is translocated 
into ER by C-teminal hydrophobic domain of C. However, signal peptidase cleavage is 
delayed until the viral serine protease cleaves upstream of this region sequence to generate 
the mature form of C protein (Lobigs M. and Lee E., 1993; Amberg Sm., et al., 1994; 
Yamshchikov VF. and Compans RW., 1994). In addition, E protein expression influences 
the rate of this signalase cleavage (Lorenz IC., et al., 2002). The cleavage of this protein by a 
furin-like protease occurs within the trans-Golgi network and is necessary for particle 
maturation (Brinton MA., 2002). The conversion of immature virus particles to mature 
virions occurs in the secretory pathway and coincides with cleavage of prM into pr and M 
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fragments by the Golgi-resident protease furin enzyme (Stadler K., et al., 1997). This protein 
protects virions from fusion inside acidic vesicles of the Golgi complex (Martin-Acebes 
MA., et al., 2012). The furin-like protease cleaves the prM/M membrane protein, enabling a 
conformational rearrangement in the viral particle from immature particles (Zhang Y., et al., 
2007) to mature ones (Mukhopadhyay S., et al., 2003). Modulation of the proportion of 
prM/M cleavage can also modulate the sensitivity of antibody-mediated neutralization 
(Nelson S., et al., 2008). 
The envelope (E): The envelope (E) is a transmembrane protein anchored to the lipid 
envelope by a C-terminal α-helical hairpin. It is the most immunogenic protein of the virus 
and the target for most neutralizing antibodies. The protein is glycosylated on position 154 
on most WNV strains (Beasley DW., 2005a). Glycosylation is important for efficient 
transmission in mosquito and birds (Moudy RM., et al., 2009; Murata R., et al., 2010) and 
may be related to neuroinvasiveness (Shitato K., et al., 2004). E protein contains 12 
cysteines involved in the formation of intramolecular disulfide bonds and the production of 
homodimers. E glycoprotein is organized in three domains: DI, DII, and DIII. DI links 
domains II and III (Nybakken GE., et al., 2006). DII contains a conserved region of 13 
hydrophobic amino acids that form an internal fusion loop necessary for virus fusion. DIII is 
an immunoglobulin-like domain that is thought to be involved in the interaction between 
virions and host cells to enable the virus entrance, moreover it contains multiple epitopes 
that are recognized by neutralizing antibodies. Upon acid exposure, the E glycoprotein 
undergoes conformational rearrangements and changes from dimers to trimers, exposing the 
fusion loop to enable viral fusion of the virion with cellular endosomal target membranes. 
For other flaviviruses, as tick-borne encephalitis virus, this process is triggered by 
protonation of an individual His residue on E glycoprotein (Fritz R., et al., 2008) that should 
act as a critical pH sensor. However, this hypothesis has not been validated for WNV 
(Nelson S., et al., 2009), although point mutations can modulate the fusion threshold 
(Martin-Acebes MA. and Saiz JC., 2011). 
3.2.2 VIRAL NON-STRUCTURAL PROTEINS 
Although the functions of the WNV non-structural proteins have not yet been completely 
characterized, all seven are directly or indirectly involved in viral RNA synthesis and 
additional functions for some of these proteins have been identified. Little is known about 
the interactions between the viral non-structural proteins or between viral non-structural 
proteins and cell proteins that are required for remodelling the cell environment and for 
appropriately regulating active viral RNA replication complexes at different phases of the 
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virus life cycle (Brinton MA., 2014). 
NS1: This is a versatile non-structural viral glycoprotein that has a molecular weight of 46-
56 kDa, depending on its glycosylation status. NS1 exists in multiple oligomeric forms: 
monomers, dimers (the primary form) and hexamers, and this seems to be related to its 
cellular retention or secretion stage (Brinton MA., 2002; Beasley DW., 2005a). NS1 is found 
at different cellular locations: either cell-membrane-associated (mNS1), in vesicular 
compartments within the cell or on the cell surface, and as a secreted lipid-rich, extracellular 
(nonvirion) species (sNS1) (Smith and Wright, 1985; Westaway and Goodman, 1987; 
Winkler et al., 1988; Mason, 1989; Gutsche et al., 2011). Intracellular NS1 acts as an 
essential cofactor for viral replication, it co-localizes with dsRNA and other components of 
replication complex (Mackenzie et al., 1996; Westaway et al., 1997), and inhibits Toll-like 
receptor 3 (TLR3) signalling (Wilson JR., et al., 2008). Whereas, cell surface and secreted 
NS1 antagonize complement activation, are highly immunogenic, and both the proteins and 
the antibodies it elicits have been implicated in disease pathogenesis (Chung KM., et al., 
2006; Avirutnan P., et al., 2010; Muller DA. and Young PR., 2013). Recently, a larger NS1-
related protein (termed NS1’), produced by a ribosomal frameshift near the beginning of the 
NS2A gene, has been detected in infected cells and related to neuroinvasiveness (Melian 
MB., et al., 2010). 
NS2A: This is a small hydrophobic transmembrane protein involved in the biogenesis of 
virus-induced membranes, which have a vital role in virus assembly (Leung JY., et al., 
2008). In fact, NS2A has been detected by immunogold labelling primarily within vesicle 
packets (VP), associated with labelled dsRNA (Mackenzie JM., et al., 1998). Moreover, 
NS2A has been reported to have an immunomodulatory role because it inhibits interferon-β 
promoter activation (Liu WJ., et al., 2004), and it has reported that mutations in this protein 
result in viral attenuation in vivo (Liu MJ., et al., 2006; Rossi SL., et al., 2007). Recently, an 
ER membrane topology model for flavivirus NS2A was reported (Xie X., et al., 2013): the 
N-terminal amino acids are located in the ER lumen while the C-terminal tail is in the 
cytosol. The first of five transmembrane regions located in the middle part of NS2A contains 
two helicase separated by the “helix-breaker” amino acids P85 and R84. Mutation of each of 
these amino acids in both a replicon and an infectious clone showed that R84 but not P85 
was functionally important. Interestingly, an R48E mutation attenuated both viral RNA 
replication and virion production while an R84 mutation had no effect on viral RNA 
synthesis but inhibited the production of infectious virions (Brinton MA., 2014).   
NS2B: It is also a small hydrophobic protein that interacts with the NS3 C-terminal protease 
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domain and functions as a protease co-factor (Erbel P., et al., 2006). Alanine scanning 
approaches of NS2B has revealed two sites critical for regulation of the proteolytic activity 
of NS2B-NS3 complex (Chappell KJ., et al., 2008). The interaction between NS2B and NS3 
may also confer specificity for RNA unwinding of NS3 discriminating from DNA (Chernov 
AV., et al., 2008). 
NS3: This is a highly conserved and multifunctional protein, consisting of the N-terminal 
serine protease domain localized to amino acids 1-169 and the C-terminal domain from 
residues 180-618, bearing helicase, nucleoside triphosphatase, and RNA triphosphatase 
activities, important for viral replication (Gorbalenya AE., et al., 1989; Wengler G. and 
Wengler G., 1991; Wengler G., et al., 1991a). The N- and C-terminal domains are linked via 
a flexible inter-domain, comprising residues 169-179 (Luo D., et al., 2008; Assenberg JM., 
et al., 2009). However, it is not active unless tethered to its cofactor, NS2B (Chappell KJ., et 
al., 2008a). This protease cleaves the viral polyprotein to release structural and non-
structural proteins and, thus, disruption of its activity is lethal for virus replication. NS3 (and 
also its cofactor NS2B) has been localized within paracrystalline arrays (PC) or convoluted 
membranes (CM), suggesting that these membranes are the sites of proteolytic cleavage 
(Mackenzie JM., et al., 1998). Both the ATPase and helicase activity of NS3 have been 
shown to be regulated by NS4A (Shiryaev SA., et al., 2009), and the two activities can 
function independently of each other (Borowski P., et al., 2001). Within infected host cells, 
these functions appear to be regulated by their differential localization to separate virus-
induced membranous compartments (Westaway EG., et al., 2001). All these properties of 
NS3 made of this protein and its active form, NS2B-NS3, a promising antiviral target 
(Martin-Acebes MA., et al., 2012) 
NS4A: This is a small hydrophobic protein with several transmembrane domains that has 
been localized to the viral replication complex in virus induced membranes (VP, CM and 
PC) (Mackenzie JM., et al., 1998). The C-terminal region of NS4A can be cleaved by cell 
signalase generating the 2K fragment that may be responsible of membrane rearrangements 
in infected cells (Brinton MA., 2014). In addition, it has been reported that cleavage of 
NS4A C-terminal regional in DENV acts as a signal sequence for translocation into the ER 
of the adjacent NS4B protein (Miller S., et al., 2007). NS4A has been also related, together 
with NS2A, NS2B, and NS4B, to block type I interferon signalling in flavivirus infected 
cells (Martin-Acebes MA., et al., 2012; Brinton MA., 2014). Accumulation of NS4A (and 
also NS4B) into ER of infected cells seems to be involved in induction of the unfolded 
protein response upon WNV infection. Mutations in the 2K fragments have been related to 
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resistance against the antiviral action of the interferon-inducible 2’, 5’-oligoadenylate 
synthetase 1b protein, and also to resistance against the flavivirus inhibitor lycorine thanks to 
the enhancement of RNA replication. NS4A has been proposed to also act as a cofactor 
regulating ATPase activity of the NS3 helicase (Martin-Acebes MA., et al., 2012). 
NS4B: This is a small hydrophobic non-structural protein that is hypothesized to participate 
in viral replication and inhibition of host interferon signalling (Munoz-Jordan JL., et al., 
2005). Mutations in NS4B affect viral RNA replication (Wicker JA., et al., 2006; Puig-
Basagoiti F., et al., 2007; Welte JA., et al., 2006), possibly through its interaction with NS3 
helicase (Xie X., et al., 2011) and can result in attenuation of WNV in vivo (Wicker JA et 
al., 2006; Welte T., et al., 2011). NS4B has been localized in perinuclear membranes and in 
the nucleus of WNV infected cells (Westaway EG., et al., 1997a; Pheng S. and Pei-Yong S., 
2013) where it may be involved in the formation of viral replication complex. 
NS5: This is located at the C-terminus of the viral polyprotein and is the largest and most 
conserved protein amongst members of the genus Flavivirus. NS5 contains two domains that 
have different enzymatic activities. The N-terminal region contains an S-adenosyl 
methionine methyltransferase (MTase) domain that has N7 and 2’-O MTase activities and 
also acts as guanylyltransferase (Brinton MA., 2014). This domain is necessary for capping 
the 5’ end of the viral RNA that is performed by sequential methylation reactions. The C-
terminal portion contains conserved sequence motifs characteristics of all RNA-dependent 
RNA polymerase for replication of viral genome (RdRp domain) (Martin-Acebes MA., et 
al., 2012). The methyltransferase activities together with the polymerase activities of NS5 
are genetically validated to be essential for viral replication (Pheng S. and Pei-Yong S., 
2013). This protein localizes to virus induced membranes in infected cells and colocalizes 
with dsRNA at viral replication complexes (Mackenzie JM., et al., 2007a). Due to the lack 
of proof-reading activity of NS5, WNV populations display a variable level of sequence 
diversity that favours selection of variants in response to selective pressures. NS5 is also a 
potent antagonist of interferon signalling to evade of host innate immune defences (Laurent-
Rolle M., et al., 2010). Both the capping and RdRp activities made of NS5 also a promising 
antiviral target (Martin-Acebes MA., et al., 2012). 
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3.3 WNV REPLICATION CYCLE 
The WNV life cycle consists of 4 principal stages: attachment/entry, translation, replication, 
and assembly/egress. WNV enters cells via receptor-mediated endocytosis after E protein 
interacts with one or more cell surface receptor(s). It is not completely clear which cellular 
receptors are involved in WNV binding, however DC-SIGN, several glycosaminoglycans, 
mannose receptor, c-type lectins and, although still controversial, integrin αvβ3 have been 
proposed as potential receptors (Tassaneetrithep B., et al., 2003; Lee E., et al., 2004; Davis 
CW., et al., 2006; De Filette M., et al., 2012; Martin-Acebes MA., et al., 2012). After 
binding to the cell, the viral particles are internalized into host cells via a clathrin dependent 
mechanism. Rab 5 was reported to be required for the cellular WNV entry (Krishnan MN., et 
al., 2007). The virus-containing endosome matures during internalization from the cell 
surface, with the pH dropping from neutral to slightly acidic in the early endosome and 
becoming more acidic during maturation to the late endosome. Acidification inside the late 
endosome triggers rapid conformational changes on the E protein resulting in fusion between 
the viral and endosomal membranes, and release of the virus nucleocapsid into the 
cytoplasm for genome uncoating (Gollins SW., et al., 1986; Modis Y., et al., 2004; 
Mukhopadhyay S. et al., 2005; Martin-Acebes MA., et al., 2012). The optimal pH for 
conformational rearrangements and viral fusion is 6.3-6.4, and this fusion process is 
dependent on the presence of cholesterol in the target membrane (Moesker B., et al., 2010; 
Martin-Acebes MA., and Saiz JC., 2011). Once viral RNA genome reaches the host cell 
cytoplasm it is translated into a single polyprotein, which is proteolytically processed by 
viral and host proteases to generates structural and non-structural proteins involved in viral 
replication and viron assembly. Whereas the cleavages at the junction C-prM, prM-E, E-
NS1, NS4A-NS4B (Nowak T., et al., 1989), and likely also NS1-NS2A (Falgout B., et al., 
1995), are performed by the host signal peptidase located within the lumen of ER, the 
remaining peptide bonds are cleaved by the virus encoded NS3 protease. The structural 
proteins form the virion that encapsidates the viral RNA, and the non-structural proteins 
form the replication complex that is required for synthesis of viral RNA (Suthar MS., et al., 
2013). The original viral RNA is replicated by viral and cellular proteins into multiple copies 
to be used in the production of new virions. WNV replication requires the viral protein NS5, 
which is an RNA-dependent RNA polymerase (Rice CM., et al., 1986; Poch O., et al., 
1989). An “antisense” negative strand RNA is produced by this enzyme, which then serves 
as a template for the synthesis of many new copies of the infectious positive strand RNA 
genome (De Filette M., et al., 2012). WNV induces changes in the cellular environment in 
! 18!
order to create conditions more appropriate for viral replication and undergo notable 
intracellular membrane remodelling. In particular, viral remodelling of ER (endoplasmic 
reticulum) membranes to form a network of replication complex provides a 
microenvironment required for productive viral replication (Bidet K., et al., 2014). These 
structures are important replication and virus protein processing and are termed vesicle 
packets (VP), paracrystalline arrays (PC) and convoluted membranes (CM) (Westaway EG., 
et al., 1997; Mackenzie JM., et al., 2001). Viral replication takes place at VPs, which are 
generated as invaginations of the membrane of ER and contact by pores with the cell 
cytoplasm. VPs contain dsRNA replication intermediates, and assembled virions bud into the 
ER (Gillespie LK., et al., 2010; Matin-Acebes MA., et al., 2012). A specific role of 
cholesterol and fatty acids in WNV-induced membrane structures has been proposed, and 
proteasome activity seems to be also important for viral replication (Mackenzie JM., et al., 
2007; Gilfoy F., et al., 2009; Heaton NS., et al., 2010; Fernandez-Garcia MD., et al., 2011; 
Matin-Acebes MA., et al., 2012). Apart from providing the adequate platform for viral 
replication, these membrane rearrangements may also play a role for the evasion of innate 
immune response by interfering with the interferon signalling machinery (Hoenen A., et al., 
2007; Mackenzie JM., et al., 2007). In addition, replication of WNV, accumulation of non-
structural proteins at the ER induces ER stress activating the unfolded protein response and 
also induces apoptosis of infected cells (Parquet MC., et al., 2001; Medigeshi GR., et al., 
2007; Ambrose RL., et al., 2011). Following replication and translation, genomes are 
packaged into virions, which travel to the cell surface in exocytic vesicles and mature 
through the ER-Golgi secretion pathway (Rice CM., 1996; Rossi SL., et al., 2010). This 
maturation process requires the cleavage of prM/M protein by a furin-like protease located at 
the acidic environment of the trans-Golgi network (Brinton MA., 2002). After maturation, 
viral particles are released by exocytosis from surface of infect cells (Rossi SL., et al., 2010).  
 
! 19!
 
Figure 6: West Nile virus replication cycle. Schematic view of West Nile virus replication 
cycle in an infected cell. Electron micrograph of West Nile virus-infected Vero cells 
illustrate distinct snapshots from infectious cycle. WNV infects a wide range of target cells. 
Virion entry is initiated after the envelope protein, E, engages an unknown cellular receptor 
(or receptors) (step 1), followed by receptor-mediated endocytosis of the virus (step 2). The 
low-pH environment within the endosomal vesicle triggers viral fusion with the endosomal 
membrane, leading to virion uncoating and release of the viral positive-sense single-stranded 
RNA ((+)ssRNA) genome into the cytoplasm (step 3). The viral (+)ssRNA is translated into 
a single polyprotein at the ER and cleaved into mature proteins by the viral serine protease 
non-structural protein 2B–3B (NS2B–NS3) and cellular proteases (step 4). The NS proteins, 
including the viral RNA-dependent RNA polymerase NS5, form the replication complex for 
the synthesis of full-length negative-sense ssRNA ((–)ssRNA) intermediates. These serve as 
templates for the synthesis of full-length (+)ssRNAs. The viral capsid protein, C, is 
responsible for encapsidating viral genomic RNA, with assembly occurring on rough ER 
membranes (step 8). Immature virions are transported through the host secretory pathway, 
resulting in glycosylation of the viral E protein and host cell furin mediated-cleavage of the 
protein prM to the mature membrane protein, M (step 5). Mature virions are transported to 
the plasma membrane and released by exocytosis (step 6) (Martin-Acebes MA., et al., 2012; 
Suthar MS. et al., 2013). 
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3.4 MOLECULAR CLASSIFICATION 
First classifications of WNV were based on cross-neutralization reactions and revealed that 
WNV is a member of the Japanese encephalitis virus serocomplex. This complex includes 
also other neurovirulent viruses such as Murray Valley encephalitis virus, St. Louis 
encephalitis virus, or Usutu virus (Poidinger M., et al., 1996; Beasley DW., 2005). Even 
though WNV has a single serotype, it nonetheless exhibits considerable genetic variation 
(Bondre VP., et al., 2007). Phylogenetic classification of WNV remains dynamic, with the 
large increase in genome sequence and surveillance data in recent years. Present analysis 
support that WNV aligns into at least seven different lineages (Fig. 7), on the basis of 
nucleic acid homology, with the major lineages diverging by 25%-30% nucleotide 
differences (Hubalek Z., et al., 1998; Lanciotti RS., et al., 1999; Lvov DK., et al., 2004; 
Mackenzie JS., et al., 2009; May FJ., et al., 2011; Papa A., et al., 2011). WNV strains that 
cause disease in humans and horses belong into the major lineages 1 and 2 (Marka A., et al., 
2013; Di Sabatino D., et al., 2014), while other lineages have been sporadically detected in 
mosquitoes and birds but not associated with human disease (Vazquez A., et al., 2010).  The 
phylogenic classification does not consistently correlate with the geographical distribution of 
WNV, which may be attributed to the broad dissemination of the virus by migrating bird 
species (Gray TJ. and Webb CE., 2014).  
3.4.1 LINEAGE 1 
Lineage 1, the largest and the most widespread, contains WNV strains isolates from Europe, 
Africa, Australia, Asia, North and Central America, as well as the Middle East (Hosseini 
NS., et al., 2014; Gray TJ. and Webb CE., 2014; Lanciotti RS., et al., 1999). Lineage 1 can 
be further subdivided into three different clades: 1a, 1b and 1c. Clade 1a is the most widely 
distributed and contains strains from the Americas (including the NY99 strain), Europe, 
Africa, the Middle East and Israel. Until recently, clade 1a comprises most of the isolates 
associated with outbreaks of human encephalitis, including the ongoing epidemic in North 
America (Lanciotti RS., et al., 1999). Interestingly, this clade displays close genetic 
relationship between geographically distant areas which are supposed to be the result of 
WNV introductions via migratory birds (Martin-Acebes MA., et al., 2012) This clade can 
further be divided in six clusters with distinct evolutionary histories (May FJ., et al., 2011). 
Sublineage 1b, contains the Australian Kunjin virus, that is an uncommon cause of human 
disease endemic to Australia and it is probably found in South East Asia and Papua New 
Guinea (Hall RA., et al., 2001; Gray TJ., et al., 2011; Rossi SL., et al., 2012; Hosseini NS., 
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et al., 2014). While few human cases were reported, a major epidemic of illness in horses 
was reported in southeast Australia in 2011 (Frost MJ., et al., 2012). Clade 1c is only found 
in India. It has been proposed that isolates previously classified as sublineage 1c be 
reassigned to a new lineage 5 (Lanciotti RS., et al., 2002; Beasley DW., 2005; Bronde VP., 
et al., 2007). The fact that only one endemic genotype has been detected in India (1c) and 
one in Australia (1b), suggests that WNV was successfully introduced into these locations 
only once, as well as it was the casa in the American continent, where WNV was introduced 
in 1999 in the East Cost of the US (Lanciotti RS., et al., 1999; May FJ., et al., 2011). The 
first North American WNV isolate was most closely related to a strain isolated from a dead 
goose in Israel (lineage 1) during the 1998 outbreak, suggesting that North American WNV 
was derived from this epidemic (Lanciotti RS., et al., 1999). However, recent data suggest 
that the epidemic in Israel in 1998 was not the direct progenitor of North American 
epidemics, but rather that both epidemics originated from the same (unknown) location (May 
FJ., et al., 2011).   
3.4.2 LINEAGE 2 
Lineage 2 WNV, until the mid-2000s, was predominantly limited to sub-Saharan Africa and 
Madagascar, where it has been a cause of mild febrile illness in humans, rarely progressing 
to severe disease and typically not associated with outbreaks (Lanciotti RS., et al., 2002). 
However, in 2004 and 2005, WNV belonging to lineage 2 was first identified in wild birds in 
Hungary, with subsequent rapid spread to central Europe (Bakonyi T., et al., 2005; Bakonyi 
T., et al., 2006). Since 2004, lineage 2 has been observed in central and Eastern Europe. In 
2010 it caused outbreaks in Romania and Greece and in 2011 it was detected for the first 
time in Italy (Bakonyi T., et al., 2006; Platonov AE., et al., 2008; Sirbu A., et al., 2010; Papa 
A., et al., 2010; Bagnarelli P., et al., 2011; Papa A., et al., 2011). These lineage 2 viruses 
have been implicated in avian, equine, and human cases of neuroinvasive disease with 
associated deaths, including cases reported in Russia, Hungary, Italy and Greece (May FJ., et 
al., 2011; Papa A., et al., 2011; Barzon L., et al., 2013; Magurano F., et al., 2012). The 
Greek and Italian strains showed the highest homology to Hungarian and South African 
strains, differing from the Russian lineage 2 strains. This means that at least two lineage 2 
strains are circulating in Europe causing severe neuroinvasive infections in birds, horses and 
humans (Papa A., 2012; Papa A., et al., 2012). Although there are exceptions, in general, 
lineage 1 viruses are considered to be more virulent than the lineage 2 viruses (De Filette 
MD., et al., 2012): lineage 1 (clade 1a) viruses can cause severe human neurologic disease 
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whereas lineage 2 viruses generally cause a mild, self-limiting disease. Both, lineage 1 and 
2, are now considered endemic in southeastern Europe, with an over 700% increase in cases 
reported in the region since 2009 (European Centre for Disease Prevention and Control, 
2013).  
3.4.3 LINEAGE 3 
Lineage 3 WNV was first isolated near the Austrian and Czech Republic border in 1997. 
WNV belonging to lineage 3 has also referred as Rabensburg virus 97-103, named after the 
nearby Austrian town where the first infected Culex pipiens mosquitoes were isolated 
(Hubalek Z., et al., 1998; Bakonyi T., et al., 2005; Hosseini NS., et al., 2014). On the basis 
of genomic and antigenic diversity, it has been suggested that Rabensburg virus be assigned 
a new species within the Japanese encephalitis virus group (Bakonyi T., et al., 2005). 
Lineage 3 strain has not been isolated from humans, and the pathogenic potential remains 
uncertain, particularly as Rabensburg virus has been shown not to infect mammalian or 
avian cell cultures, nor infect experimentally exposed birds (Aliota MT., et al., 2012).  
3.4.4 ADDITIONAL PROPOSED LINEAGES  
Additional lineage subdivisions have been proposed for novel flavivirus isolates, including 
lineage 4 that contains a new variant of WNV (strain LEIVKrnd88-190), which was isolated 
in 1998 from Dermacentor marginatus ticks in a valley in the northwestern Caucasus 
Mountains of Russia (Bakonyi T., et al., 2005; Hosseini NS., et al., 2014). Lineage 5 WNV 
has been proposed for a group of human and mosquito isolate from India as early as the 
1950s and cluster to form sublineage 1c  (strain 804994) (Bondre VP., et al., 2007; Botha 
EM., et al., 2008). Lineage 6 WNV has been proposed for virus isolated from C. pipiens 
mosquitoes in southern Spain in 2006, strain HU2925/06, and forms a common evolutionary 
branch with lineage 4 (Vazquez A., et al., 2010). In addition to these minor lineages, the 
African virus Koutango (KOUV), first isolated in Senegal, is currently recognized as a 
separate species but could be considered as a seventh WNV lineage (De Filette MD., et al., 
2012; Pesko KN. and Ebel GD., 2012). The human pathogenicity of lineages 4, 6 and 7 
WNV is poorly understood, with human infection not reported (Gray TJ. and Webb CE., 
2014). 
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Figure 7. West Nile Virus (WNV) genetic diversity, evaluated using genetic alignment 
of complete genomic sequences. GenBank accession numbers are indicated on the tree 
branches of each virus; the first two or three letters stand for the country or the USA state 
reporting WNV (It = Italy, Sp = Spain, Mo = Morocco, Fr = France, Ken = Kenya, Rus = 
Russia, Tu = Tunisia, Hu = Hungary, Ro = Romania, Arg = Argentina, Tx = Texas, NY = 
New York, Is = Israel, Ind = India, Eg = Egypt, Kun = Kunjin Australia, SA = South Africa, 
Ug=Uganda, Ser = Serbia, and Gr = Greece) and the numbers indicate the year of isolation 
(96 = 1996, 10 = 2010). Japanese encephalitis virus (JEV), a closely related flavivirus, was 
used as an outgroup. The rooted phylogenetic tree was constructed using neighbor-joining 
with Jukes-Cantor parameter distances (scale bar) in MEGA (MEGA software, version 5.2) 
(Tamura K., et al., 2011). A bootstrapped confidence interval (1,000 replicates) and a 
confidence probability value based on the standard error test were also calculated using 
MEGA. The WNV strains responsible for recent human or equine outbreaks are underlined. 
The complete sequences of the most recent Romanian and Russian lineage 2 variants are not 
available, but at least two introduction events of lineage 2 strains have occurred in Europe: 
divergent lineage 2 strains have been observed in Romania/Russia and 
Hungary/Greece/Italy/Serbia/Austria (Ciccozzi M., et al., 2013; Donadieu E., et al., 2013). 
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3.5 TRANSMISSION CYCLE 
WNV is maintained in nature in an enzootic transmission cycle between avian hosts and 
ornithophilic mosquito vectors (Fig. 8). Mosquitoes become infected by feeding on birds that 
carry virus particles in sufficient concentrations in their blood (Marka A., et al., 2013). Apart 
birds, the virus can be transmitted to other animals including horses and humans as well 
(Hayes EB., et al., 2005). Humans and horses are considered incidental or “dead-end” hosts 
for WNV, as the low concentration of virus within the blood (viremia) in mammals is 
usually insufficient to infect a feeding naïve mosquito and maintaining the transmission 
cycle (Bowen RA., and Nemeth NM., 2007; Rossi SL., et al., 2010). Although human cases 
occur primary after mosquito inoculation, infection after blood transfusion, organ 
transplantation, and intrauterine transmission has reported (Hayes EB., et al., 2005).  
 
3.5.1 VECTORS: MOSQUITOES AND OTHER ARTHROPODS  
The ability of different mosquito species to acquire and transmit WNV is highly variable 
(Colpitts TM., et al., 2012). At least over 60 species of mosquitoes from 11 different genera 
have been described as competent vectors. Mosquitoes of the genus Culex are the 
predominant vectors in the enzootic cycle throughout the range of the virus distribution, 
although the particular species of Culex varies according to geographic locations (Martin-
Acebes MA., et al., 2012). In North America Cx. pipiens, Cx. restuans, Cx. 
quinquefasciatus, Cx. salinarus, Cx. tarsalis, and Cx. nigripalpus have been described as the 
most efficient competent vectors; although other species such as Aedes albopictus, Aedes 
vexans, Ochlerotatus japonicus and Ochlerotatus triseriatus may also play role on viral 
transmission as bridging vectors that can transmit the virus to mammals (Brault AC., 2009). 
In Europe, the virus has been isolated from more than 40 different species, being again those 
of the Culex species the main vectors (Zeller HG. and Schuffenecker I., 2004). Several other 
species have been also implicated in the transmission cycle as competent vectors in other 
geographical areas, Cx. univittatus in Africa, Cx. annulirostris in Australia, and Cx. vishnui 
and Cx. tritaeniorhynchus in Asia (Hall RA., et al., 2002; Hayes EB., et al., 2005; Brault 
AC., 2009).  
Vector competence varies between species and within populations of individual species. The 
C. pipiens complex contains two genetically distinct forms: pipiens and molestus that differ 
in physiology and behavior with obvious implications to their epidemiological importance. 
Form pipiens is thought to be exclusively ornithophilic, while the urban form molestus will 
feed on mammals. The two forms have been shown to not interbreed in the northern Europe, 
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in contrast to US and southern Europe population, which contain individuals with hybrid 
genetic signatures (pipiens x molestus) that may generate bridge vectors, disposed to feed on 
both birds and mammals. Indeed, US populations of C. pipiens, as well as C. nigripalpus and 
C. tarsalis, have been demonstrated to shift their feeding from birds to mammals in the late 
summer and early fall, and therefore may act as bridge vectors to infect equid and human 
hosts (Kramer LD., 2008).  
Laboratory analyses have shown that C. tarsalis mosquitoes become infected after 
consumption of blood meals with viral concentrations over 107 PFU/mL, whilst only up to 
30% do it if the concentration is in the 105 PFU/mL range (Goddard LB., et al., 2002). On 
the other hand, different species of mosquitoes inoculate quite variable doses of WNV (103.4 
PFU to 106.1 PFU) into vertebrate hosts during natural feeding, of which around 102 PFU are 
directly inoculated into the blood (Styer LM., et al., 2007).  
The mechanism(s) of WNV perpetuation overwintering and years may vary by region and 
country, but possible mechanisms include continuous low-level virus transmission, 
reinitiation after reintroduction of virus by migratory birds from locations where virus is 
active year-round, vertical transmission to females about to enter reproductive diapause in 
winter, and recrudescence of low levels of virus in chronically infected birds when 
mosquitoes are active (Anderson JF. and Main AJ., 2006; Nasci RS., et al., 2001).  
Beside from mosquitoes, WNV has been sporadically isolated in other arthropods: WNV has 
been isolated repeatedly in Russia from soft ticks (Argasidae). In addition, soft ticks have 
been demonstrated to transmit virus in the laboratory, and nonviremic transmission has been 
demonstrated. Hard ticks (Ixodidae) allow the virus to pass transstadially, but are 
incompetent vectors. Moreover, other arthropods have been suggested as alternative vectors, 
including dermanyssoid mites, swallow bugs, and hippoboscid flies, but their role in the 
transmission cycle is not clear (Martin-Acebes MA., et al., 2012).  
 
3.5.2 BIRDS 
Birds are the natural reservoir of WNV. More than 300 avian species representing over 200 
birds families from North America have been reported as susceptible to WNV infection after 
its first introduction in 1999, confirming their role as primary vertebrate in the enzootic cycle 
(Martin-Acebes MA., et al., 2010; Kramer LD., 2008). Many studies have been conducted to 
determine the precise role of birds in the transmission of the virus and have demonstrated 
that birds vary significantly in susceptibility and response to infection, with a great diversity 
in the profile of viremia among the different avian species. Various experimental studies 
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have estimated that the limit, for mosquitoes to become infected after consumption of blood 
meals, is of 105 plaque forming units (PFU) viral concentration and different birds species 
can develop sufficient viremia titres before the birds become moribund and die a few days 
after being infected in order to allow the transmission of the virus to the feeding mosquitoes. 
These birds belong to the orders of Passeriformes (corvids, sparrows, finches, etc.), 
Charadriiformes (woodcocks, gulls, etc.) Strigiformes (owls, eagle owls, etc.) (Komar N., et 
al., 2003; Beasley DW., 2005). In contrast, species of the order of Paciformes 
(woodpeckers), Columbiformes (doves, pigeons, etc.) and Anseriformes (ducks, geese, etc.) 
develop lower viremia titres, in many cases insufficient to transmit the virus in mosquitoes 
and they do not contribute in the epizootic cycle (Marka A., et al., 2013).  
Feeding by infected mosquitoes is the most common route of infection, but transmission to 
birds also has been demonstrated by direct contact via the fecal-oral route: many avian 
species shed large quantities of virus in their feces or oral secretions when infected (Komar 
N., et al., 2003), allowing direct transmission from bird-to-bird and even from bird-to-
human. Experimental oral infection of birds has been demonstrated (McLean RG., et al., 
2001) and prey-to-predator infection through ingestion of infected mosquitoes or of carrion 
by omnivorous birds such as corvids and raptors has been suggested (Garmendia AE., et al., 
2000).  
 
3.5.3 HUMANS, HORSES AND OTHER ANIMALS  
Thirty species of mammals and occasionally other vertebrates including reptiles and 
amphibians have been found infected with WNV. Generally, humans, horses and other 
mammals infected in a spillover transmission are considered “dead end” hosts and their role 
in the transmission cycle is less significant than that of birds, because viral replication does 
not yield significant viremia to infect feeding mosquitoes. Enzootic in equines have occurred 
in the US, France, Italy, Marocco and in Israel. Unvaccinated equines develop infections 
ranging from asymptomatic to encephalitic disease, and demonstrate a case-fatality rate of 
about 25%. Because of their low viremias, they are considered incidental hosts in the 
transmission cycle. In experimental infections of horses with WNV, viremia levels are 
around 103 PFU/mL (Bunning ML., et al., 2002), thus being usually insufficient to sustain 
infectivity cycles (Martin-Acebes MA., et al., 2010). Several other animal species have been 
described as susceptible to WNV infection, with or without clear evidence of disease, 
including domestic and wild mammals such as: dogs, cats, pigs, cows, llamas, sheep, 
alpacas, deers, reinders, raccoons, bears, wolfs, squirrels, chipmunks, rabbits, and bats, 
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among others (Beasley DW., 2005; Blitvich BJ., 2008). As it has described for humans and 
horses, in most cases the viremia raised in these animals is low, only for rabbits and 
chipmunks, have been demonstrated in the laboratory to mount sufficiently high levels of 
virus in the blood to infect a small portion of feeding Culex spp. mosquitoes, but generally is 
probably not enough to initiate a new transmission cycle (Martin-Acebes., MA. et al., 2012). 
Apart from mammals, several reptiles and amphibians, such as snakes, crocodiles, alligators, 
iguanas and frogs (Kostiukov MA., et al., 1985; Steinman A., et al., 2003; Klenk K., et al., 
2004; Steinman A., et al., 2006) have been also described as susceptible to WNV infection 
and some of them raise high viremia. In the US and Mexico, farmed alligators raised at high 
temperatures in crowded conditions demonstrated significant mortality and mount high 
viremia. Transmission appears to occur directly between alligators, as well as through 
ingestion of uncooked infected horse meat. However, the real contribution of animals other 
than birds and mosquitoes in maintaining WNV cycle in nature is still uncertain (Martin-
Acebes MA., et al., 2010). 
 
3.5.4 NON-VECTOR-BORNE TRANSMISSION  
Even though the main mode of WNV transmission to vertebrate is via infected mosquito 
bite, it has been documented that alternative less common modes of non-vector-borne 
transmission in humans also exist: through solid organ transplantation from an infected 
donor to healthy recipient; the placenta from an infected mother to her fetus (vertical 
transmission), occupational infection concerning mainly laboratory professionals and 
through transfusion of infected blood and blood products (Martin-Acebes MA., et al., 2010; 
Marka A., et al., 2013). The first case of virus transmission through transfusion of red blood 
cells, platelets and fresh-frozen plasma has been reported in 2002 (Francis RO., et al., 2012) 
which drove, in 2003, to consequent screening of six million blood units with NAT test 
resulting in the removal of 818 positive for the virus units (Iwamoto M., et al., 2003; Pealer 
LN., et al., 2003; Hayes EB. and O’Leary DR., 2004;  Paisley JE., et al., 2006).  Routine 
testing of American Red Cross during 2003-2004 identified 540 donations that were WNV 
RNA positive but, although this technique is the one widely used for blood unit examination, 
a case of transmission followed by failure of NAT to detect units with a low viremia level 
was reported in Nebraska (De Oliveira AM., et al., 2004). In addition, in 2002 was reported 
the WNV transmission through solid organ transplantation from an organ donor, probably 
infected through blood transfusion, to four transplant recipients (CDC 2002; Iwamoto M., et 
al., 2003). Currently, there is not any national policy that requires organ donors screening, 
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but serious cases of neuroinvasive disease in recipients implies a need for ELISA and NAT 
testing of donors during transmission season (Inojosa WO., et al., 2012). In the same year, 
was reported the first case of transplacental WNV transmission in humans: a woman WNV 
infected, delivered at term a live infant that was positive for WNV-specific IgM and 
neutralizing antibodies with chorioretinits and severe cerebral abnormalities (white matter 
loss, focal cerebral destruction) (CDC 2002). In 2002, another case of probable non-vector-
borne transmission of WNV through breast milk was reported but since there was no 
confirmed case reported from that time (Hayes EB., et al., 2004; Hayes EB., et al., 2005; 
Hinckley AF., et al., 2007). Two cases of laboratory-acquired infection were reported in 
USA. The most probable mode of transmission was through percutaneous inoculation 
(James FC., McCulloch CE., 2002; Sampathkumar P., 2003; Hayes EB., et al., 2005) or even 
through exposure to aerosol (Hayes EB., et al., 2005), as shown previously in mice (Nir Y., 
et al., 1965) or, as well as two turkeys breeders, they were handling were WNV infected. 
Nonetheless, the mode of transmission to these workers remains unknown (CDC 2003). 
 
 
 
Figure 8. Diagram of the WNV transmission cycle. The maintenance of WNV in nature 
depends upon many avian and mosquito species. Humans and other incidental hosts, like 
horses, become infected when WNV-infected mosquito takes a bloodmeal from them (Rossi 
SL., et al., 2010). 
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3.6 EPIDEMIOLOGY OF WNV IN HUMANS 
The epidemiology of WNV is continuously changing. WNV was originally isolated from the 
blood of a febrile woman in the West Nile province of Uganda in 1937 (Smithburn KC., et 
al., 1940). Subsequent isolations took place some years later in Egypt (Melnick JL., et al., 
1951) Africa, Europe, Asia (Hubalek Z. and Halouzka J., 1999; Hayes CG., 2001) and then 
in Australia (Hubalek Z. and Halouzka J., 1999; Hall RA., et al., 2002; Zeller HG., et al., 
2004; Hayes EB., et al., 2005), showed that the virus was widely distributed. Before 1994, 
outbreaks of WNV were sporadic with low clinical incidence that occurred primarily in the 
Mediterranean region, Africa and east Europe and WN disease was considered as minor risk 
for humans and horses. However, in the mid-1990s, WNV re-emerged in the Mediterranean 
region and in the eastern Europe, where it caused more severe symptoms, particularly 
affecting the nervous system, and higher mortality than had been observed in previous 
outbreaks (Anez G., et al., 2012). In 1999, WNV caused an outbreak in New York City 
marking its first appearance in the Americas. Subsequently, WNV has spread rapidly 
throughout the Western Hemisphere, including the USA, Caribbean, Mexico, Canada and as 
far south as Argentina and Brazil (Pepperell C., et al., 2003; Morales MA., et al., 2006; 
Adrian DL., et al., 2008; Pauvolid-Correa A., et al., 2011). In North America, the virus has 
caused meningitis, encephalitis, and poliomyelitis, resulting in significant morbidity and 
mortality. Including the Australian WNV subtype Kunjin virus, WNV is the most widely 
distributed arbovirus in the world (Fig. 9) and WNV infection is considered a serious animal 
or human health treat (Kramer LD., et al., 2007; Anez G., et al., 2012). 
3.6.1 WORLDWIDE WNV EPIDEMIOLOGY  
The virus was initially isolated in December 1937, from a 37-years-old, febrile woman in the 
West Nile district in the Northern Province of Uganda, currently the Arua district, during an 
epidemiological study defining the endemic zone of yellow fever (Smithburn KC., et al., 
1940). Serum from the febrile case was inoculated intracerebrally in mice, with the 
subsequent viral particles shown to cause an encephalitic illness in selected vertebrate hosts. 
Since that time, the virus was not observed again until the 1950s when there were some 
sporadic reports of WNV circulation in Albania, Bulgaria, Belarus, Ukraine, and Moldavia 
(Hubalek Z. and Halouzka J., 1999) and caused the first WNV epidemics in Israel and Egypt 
(Melnick JL., et al., 1951; Bernkopf H., et al., 1953). In 1951 was reported the first 
outbreaks of human disease in Israel, with 123 cases of non-neuroinvasive disease. Since 
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were also reported the following year, while neuroinvasive cases (West Nile Neuroinvasive 
Disease, WNND) were recorded in 1957 and 1962 (Hayes CG., 2001). In Egypt, a large-
scale epidemiological investigations and serosurveys brought up to light high WNV 
endemicity in southern parts of the Nile delta in contrast to a low one in the parts 
neighboring to the Mediterrean coast (Bernkopf H., et al., 1953). This report was the first to 
describe the seasonal pattern of WNV transmission, and to propose the natural enzootic 
cycle of WNV transmission between mosquitoes and birds (Hurlbut HS., et al., 1956). Other 
than sporadic epidemics was recorded in France in summer 1962, with several human cases 
of encephalitis, while two years later 13 human cases were reported and the virus was 
isolated from the blood of two entomologists as well (Murge B., et al., 2001). More recent 
outbreaks were reported in South Africa in 1974 where WNV disease caused approximately 
10.000 human fever cases (Jupp PG., 2001; McIntosh BM., et al., 1976). Since that time, 
only sporadic outbreaks with low clinical incidence occurred and WNV was rarely seen and 
was considered of only minor importance to public health, but in the mid-1990s, the 
epidemiology of WNV apparently changed. Epizootics and epidemics of severe neurologic 
disease in horses, birds, and humans began to occur with increasing frequency (Tsai TF., et 
al., 1998; Hubalek Z. and Halouzka J., 1999; Bin H., et al., 2001; Giladi M., et al., 2001; 
Marfin AA. and Gubler DJ., 2001; Murgue B., et al., 2001; Murgue B., et al., 2001; Nash 
D., et al., 2001; Platonov AE., et al., 2001). The first cases of WNV in its lethal encephalitic 
form were reported in Algeria in 1994 with a total of 50 cases of WNV human infections 
including 20 WNND and one death (De Filette M., et al., 2012). Then, in 1996 the first 
large-scale epidemic took place in Bucarest, Romania, where WNV emerged as major cause 
of arboviral encephalitis. This outbreak was characterized by a high number of 
neuroinvasive cases with 393 recognized human cases of encephalitis and 17 deaths 
recorded in people over 50 years old (Tsai TF., et al., 1998; Campbell GL., et al., 2001). 
One year later, an epidemic took place during September-December with 173 WNND cases 
and eight deaths (Murgue B., et al., 2001). After 1996, outbreaks of West Nile viral 
encephalitis in people and horses were reported with increasing frequency in the 
Mediterranean basin (Hubalek and Halouzka., 1999; Triki H., et al., 2001), Russia (Platonov 
AE., et al., 2001) and Australia (Brown A., et al., 2002). In 1997, a new strain of WNV that 
kills young domestic geese (Anser spp.) was isolated in Israel (Malkinson M. and Banet C., 
2002). WNV activity, with or without recorded human or horses clinical cases, have been 
lately reported in Algeria, Marocco, Egypt, Israel, Romania, Russia, Poland, Czech 
Republic, Hungary, Croatia, Serbia, France, Portugal, Spain, and Italy, which overall, have 
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accounted for hundreds of cases and dozen of deaths (Zeller HG. and Schuffenecker I., 2004; 
Calistri P., et al., 2010). In 1999, in the Volgograd region, Russia, 826 patients showed a 
clinical picture resembling that of WNND, but finally 183 was the number of confirmed 
WNV cases, 84 of which were diagnosed as encephalitis and 40 persons died (Platonov AE., 
2001). In Europe, there is a history of recognized WNV outbreaks, characterized by human 
neuroinvasive disease, dating back to the mid-1990s. However, since 2008, there has been an 
unpredicted increased WNV activity in Hungary (2008–2009) (Bakonyi T., et al., 2013) and 
in Italy (2008–2009) (Rizzo C., et al., 2012), including the sustained emergence of lineage 2 
WNV, with a rapid rise in the number of cases of neuroinvasive disease of animals and 
humans (Danis K., et al., 2011; CDC 2013). In 2012, there was a peak of 937 WNV cases in 
Europe and surrounding countries, with ongoing activity in 2013, with preliminary data 
reporting 783 WNV human cases, including 86 in Greece and 302 in Serbia (Gray TJ. and 
Webb CE., 2014). 
Geographic expansion of WNV to the Western Hemisphere was detected in 1999. The 
epicenter of the outbreak took place in the Queens section of New York City and, by the end 
of the 1999 where the virus caused 62 human cases of severe and fatal neurologic disease 
including seven deaths. Numerous equine cases were documented, including an epizootic on 
Long Island, New York, with 25 clinical cases with nine deaths and an enormous mortality 
of birds, particularly among corvids (Nash D., et al., 2001; Ostlund EN., et al., 2001; Zeller 
HG. and Schuffenecker I., 2004; Hayes EB., et al., 2005; Murray KO., et al., 2010). Since 
then, WNV has spread quickly across the country, being, so far, responsible for over 1.100 
fatalities, over 12.000 cases of meningitis/encephalitis, and more than 30.000 diagnosed 
human infections (http://www.cdc.gov). Genetic sequence studies have shown that the strain 
introduced in US, belonging to lineage 1, was identical to the WNV that caused the epizootic 
in domestic geese in Israel in 1998, but is still a mystery how the virus traversed the Atlantic 
Ocean (Beasley DW., et al., 2002; Brault AC., et al., 2004). The epizootic was soon spread 
across 48 contiguous states in the following years (Marfin AA. and Gubler DJ., 2001; Zeller 
HG. and Schuffenecker I., 2004): in 2000 to New Jersey and Connecticut, in 2001 to Florida, 
Louisiana, Maryland and Massachusetts and in 2002 to almost all states, and involved severe 
and fatal neurologic disease in humans, birds, horses and several other mammalian species 
reaching its peak of 9.862 cases in 2003 (CDC 2013). The largest state concerning 
population, California, had only sporadic cases in 2002–2003 but a large outbreak took place 
in 2004 with 778 cases and 28 deaths. Other large-scale epidemics took place in Illinois (884 
cases, 2002), Colorado (2,947 cases, 2003), Nebraska (1,942 cases, 2003), South Dakota 
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(1,039 cases, 2003) and Texas (1,868 cases, 2012) (CDC 2013). Circulation of the virus to 
neighboring regions has been demonstrated through serological investigations and WNV 
activity has been reported in Canada, Central America, the Caribbean, and South America in 
mosquitoes, humans, horses, birds, and other animals, from some of which the virus has 
been occasionally isolated (Beasley DW., 2005; Blitvich BJ., 2008). In Canada, the first 
epidemic took place in 2002 with a total of 414 cases (Marka A., et al., 2013).  
In Asia, outbreaks occasionally occurred in southern regions and especially in India, while 
sporadic cases were reported in Southeast Asia (Blitvich BJ., 2008). In Australia, Kunjin 
virus, considered to belong to a sublineage of WNV (Mackenzie JS., et al., 2009), has 
caused a total of 13 human cases during the period from 1992 to 2010 (Gray TJ., et al., 
2011).  
The reason for this dramatic emergence of epizootic/epidemic disease caused by a virus that 
rarely gave rise to severe disease are not well understood (Marfin AA. and Gubler DL., 
2001). Since the mid-1990s, three epidemiologic trends have emerged regarding WNV: 1. 
Increased frequency of outbreaks in humans and horses; 2. Increase in reported cases of 
neuroinvasive disease in humans; and 3. High case fatality rates in birds coinciding with 
human outbreaks, mainly in the USA and Israel (Petersen LR and Roehrig TJ., 2001). These 
more recent outbreaks have been attributed to evolution of a new, more pathogenic WNV 
variant belonging to lineage 1 (Murray KO., et al., 2010). 
 
Figure 9. Distribution of WNV. Countries with historic or recent (2007-2010) WNV 
activity (isolations from mosquitoes, birds, horses or humans) are highlighted in red and 
blue, respectively (Rossi SL., et al., 2010). 
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3.6.2 EPIDEMIOLOGY OF WNV IN ITALY  
The first evidence of the presence of WNV in Italy occurred during the late summer of 1998 
in the Tuscany Region by the outbreak in horses, where 14 horses tested were positive for 
WNV with 6 fatal cases, while no infections in humans were recorded (Autotino GL., et al., 
2002). The lineage that caused the equine outbreak in 1998 was related to WNV strains 
circulating at that time in the Mediterranean basin. This strain was no longer detected and 
was different from the strain, called Italy/2008-2009, that was responsible of the large 
outbreaks in humans and horses that occurred in the Po river area in 2008-2009 (Barzon L., 
et al., 2009; Rossini G., et al., 2011; Sotelo E., et al., 2011). In fact, notwithstanding the 
evidence of the presence of WNV in Italy al least since 1998, with the equine outbreak in 
horses and subsequent evidence of seroconversion in sentinel animals in different risk areas, 
human disease due to WNV infection was not documented for a decade, until the first human 
case of WNV neuroinvasive disease was diagnosed in 2008 (Rossini G., et al., 2008). The 
first human cases of WNND and WNF were detected in the Po river area in northeastern 
Italy in September-October 2008: these cases included three patients with WNND who were 
resident in Emilia-Romagna region (Rossini G., et al., 2008; Rizzo C., et al., 2012) and one 
patient with WNND and one with WNF who were in Veneto region (Rossini G., et al., 2008; 
Barzon L., et al., 2009; Gobbi F., et al., 2009), following the alert from the veterinary 
surveillance that reported equine cases of WNND in the same area (Macini P., et al., 2008). 
Retrospective analysis of CSF samples collected in the Summer 2008 in Veneto region from 
patients with aseptic encephalitis or meningitis led to the identification of further four human 
cases of WNND, with symptom onset in August-September and resident in the same area of 
WNV circulation (Barzon L., et al., 2009). A further five cases of asymptomatic WNV 
infection, including four resident in the affected area, were identified by active surveillance 
of farm workers (Barzon L., et al., 2009). On the basis of phylogenetic analyses, the WNV 
strains responsible for the Italian outbreaks in 2008-2009 belonged to lineage 1 and 
constituted a distinct monophyletic group within the WMed cluster (Rossini G., et al., 2011). 
In the decade 1998-2008, a possible explanation for the absence of human cases could be 
related to the underestimation of WNV activity and the under-diagnosis of WNV disease in 
Italy, especially in the years before the first human cases were identified. However, it cannot 
also be excluded that this was due to the lack of bridge transmission to humans during this 
decade or to the circulation of less pathogenic strains that did not cause symptomatic disease 
in humans, before the emergence of a new more virulent strain in 2008. 
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In 2009, WNV circulation was reported in larger area near the Po river that involved Veneto, 
Emilia-Romagna and Lombardy regions, with occurrence of several human cases (Rizzo C., 
et al., 2009; Calistri P., et al., 2010; Capobianchi MR., et al., 2010). In the period from the 
end of August to the end of September 2009, were diagnosed cases of WNV human 
infection: 18 confirmed cases of WNND identified and two positive organ and blood donors 
(Barzon L., et al., 2009; Rizzo C., et al., 2009; Angelini P., et al., 2010). These results of 
human surveillance were in agreement with those from veterinary and entomological 
surveillance that reported involvement of a territory surrounding the Po river larger than in 
the previous year, with evidence of WNV spread to western areas (Angelini P., et al., 2010; 
Busani L., et al., 2011). The year 2010 was characterized by a decrease of WNV activity, in 
parts as a result of effective vector control measures applied in the areas of WNV circulation 
surrounding the Po river (Calzolari M., et al., 2010). In fact, in 2010, human cases of 
infection (three cases of WNND, three of WNF, and two positive blood donors) were 
detected only in Veneto region, in areas located north of those affected in 2008 and 2009 
(Barzon L., et al., 2011). An increasing WNV activity was observed in the following years 
in these new areas in Veneto region and in the nearby Friuli Venezia Giulia region: in 2011 
was reported 10 cases of WNND, two of WNF, and six positive blood and organ (Rizzo C., 
et al., 2009; Rizzo C., et al., 2012) and in 2012 occurred the largest human outbreak ever 
recorded in Italy, with 25 confirmed cases of WNND, 17 of WNF, and 14 positive blood 
donors (Barzon L., et al., 2012; Barzon L., et al., 2013). In 2011 and 2012, human cases of 
WNV neuroinvasive disease were reported also in Sardinia island: five confirmed and one 
probable WNND cases recorded in 2011 (Magurano F., et al., 2012) and two confirmed 
WNND cases in 2012 (Barzon L., et al., 2013; EpiCentro; 2013). Surveillance in other 
Italian regions notified a sporadic case of WNF in the Marche Region, Central Italy, in 2011 
(Bagnarelli P., et al., 2011) and a case of WNND in the South of Italy (Basilicata Region) in 
2012 (Barzon L., et al., 2013). In 2011, human cases of WNV neuroinvasive infections 
registered in Veneto, Friuli Venezia Giulia and Sardinia were due by lineage 1 strains (Rizzo 
C., et al., 2012), while a case of WNV fever reported in Marche region was caused by 
lineage 2 strain (Fig. 10) (Bagnarelli et al., 2011). 
In August of 2013, the epidemiology of WNV in northeastern Italy appears to be changing 
again. In fact, at least 12 human cases of WNV infection were reported in the Po area that 
was also affected in 2008–2009, while northern areas were less affected (Barzon L., et al., 
2013).  
These epidemiological data on human cases of WNV infection were in line with the results 
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from entomological and veterinary surveillance that reported WNV circulation and activity 
in the same areas where human cases were identified. In several cases, entomological and 
veterinary surveillance could predict the occurrence of human cases by reporting increased 
vector density and rate of infected mosquitoes and outbreaks in horses (Angelini P., et al., 
2010; Gobbi F., 2012; Spissu N., et al., 2013; Mulatti P., et al., 2013). 
In Italy, the onset of WNV disease in humans ranged from late July to late October, with 
peaks of cases reported in late August and early September. In patients with WNND, the 
overall percentage of death was approximately 10% and occurred generally in elderly and 
immunocompromised patients (Barzon L., et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: WNV epidemiology in Italy. Map of Italy showing the areas where different 
WNV strains were detected in the period from September 2008 to August 2013. WNV 
lineage 1 strains are indicated in blue; WNV lineage 2 strains are indicated in red (Barzon 
L., et al., 2013). 
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3.7 PATHOGENESIS 
Understanding the full range of WNV pathogenesis in humans has been difficult, mainly due 
to the difference in virulence between WNV strains and the high prevalence of 
asymptomatic or sub-clinical infections. Little has been published about human infections 
with WNV of limited virulence. The vast majority of our current knowledge regarding WNV 
pathogenesis resulted from animal models (mostly rodent) infected under controlled 
conditions with a known amount of needle-inoculated virus. On the basis of these studies 
have been identified three distinct phases of WNV pathogenesis: 1. The early phase, with 
initial infection and spread; 2. The visceral-organ dissemination phase, with peripheral viral 
amplification; and 3. The central nervous system (CNS) phase, with WNV neuroinvasion. 
These phases may not accurately reflect the course of a natural infection in humans, but this 
sequence is thought to recapitulate the stages of pathogenesis in humans following infection 
by a mosquito (Samuel MA. and Diamond MS., 2006). Nevertheless, many descriptive 
accounts have been documented following the course of infection in humans suffering from 
West Nile fever (WNF) and West Nile neuroinvasive disease (WNND) resulting from a 
virulent lineage 1 WNV infection (Rossi SL., et al., 2010).  
3.7.1 WNV PROPAGATION IN THE MOSQUITO HOST  
Female Culex spp. mosquitoes acquire WNV after taking a blood meal from an infected 
viremic animal. The virus must then infect and replicate in cells of the mosquito midgut as 
the blood meal is being processed. After replication in the midgut epithelial cells, the virus 
spreads through the mosquito haemolymph to the salivary glands and other organs (Girard 
YA., et al., 2004). Accumulation of the virus in the salivary glands will eventually result in 
high viremia in the saliva, from where it can then be transmitted to its vertebrate hosts during 
the probing process of blood feeding (Colpitts TM., et al., 2012). A key step in WNV 
transmission and vector competence is the midgut barrier, which acts as a physical and 
immune barrier through the production of antimicrobial peptides and a peritrophic matrix 
(composed of chitin, proteins, glycoproteins and proteoglycans), which together limit viral 
replication and spread within the insect (Moskalyk LA., et al., 1996). A recent study 
suggests that C-type lectins facilitate WNV dissemination in mosquitoes (Cheng G., et al., 
2010). A secreted C-type lectin protein, mosGCTL-1, binds to WNV and enhances viral 
attachment and infection through interaction with mosPTP-1, a mosquito surface protein that 
is a homologue of human CD45. WNV binds to secreted mosGCTL-1 in the haemolymph, 
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thus facilitating viral entry and invasion of different mosquito tissues. WNV infection 
triggers invertebrate innate immune programmes that can restrict infection. These include 
RNAi; innate immune signalling pathways mediated by Toll, immune deficiency (IMD) and 
JAK–STAT (Janus kinase–signal transducer and activator of transcription) proteins; and 
antimicrobial peptides (Arjona A., et al., 2011). Moreover, mosquitoes carry Wolbachia 
spp., which are symbiotic bacterial species that inhibit WNV replication in the insect (Glaser 
RL. and Meola MA., 2010). Mechanistically, Wolbachia spp. induce oxidative stress and 
reactive oxygen species in response to WNV infection, leading to activation of the Toll 
pathway and production of antimicrobial peptides, including defensins and cecropins, that 
inhibit flavivirus replication (Pan X., et al., 2012). 
3.7.2 INITIAL INFECTION, VIRAL AMPLIFICATION AND SPREAD IN HUMANS 
During feeding, infected mosquitoes probe host skin using their proboscid in order to inject 
mostly intradermally but also intravascularly pharmacologically active saliva proteins and to 
locate a blood source (Hudson A., et al., 1960; Ribeiro JM., et al., 1984; Ribeiro JM., et al., 
1985). Dermal blood vessels are the targets for hematophagous insects. In order to locate 
these structures, the proboscis must navigate through a very elastic environment that has a 
high tensile strength. To efficiently move through this environment, mosquito saliva may 
contain components that liquefy the bite site. A salivary endonuclease with a proposed 
function to facilitate probing in host skin has been identified in C. quinquefasciatus (Calvo 
E. and Ribeiro JM., 2006). As part of the feeding process, a mosquito injects saliva and the 
viral particles that it contains. Depending on the mosquito species, up to 106 plaque-forming 
units (PFU) of infectious virus can be delivered into the host per bite (Styer LM., et al., 
2007). Although many hematophagous insects can obtain a blood meal without functional 
salivary glands, the efficiency of blood feeding is severely limited (Hudson A., et al., 1960; 
Ribeiro JM., et al., 1984; Ribeiro JM., et al., 1985). In addition to viral factors that block the 
host immune response, saliva contains molecules that combat the host’s hemostatic system, 
reduce inflammation and alter host immunity (Titus R., et al., 2006) that affect viral 
pathogenesis. All hematophagous insects inject at least one vasodilator, one coagulation 
inhibitor, and one platelet inhibitor, and often the saliva includes immunomodulatory, 
digestive, and antimicrobial proteins as well (Ribeiro JM., et al., 2001; Ribeiro JM. and 
Francischetti IM., 2001; Ribeiro JM., et al., 2007; Schneider BS. and Higgs S., 2008). Mice 
inoculated intradermally with WNV subsequent to feeding by Culex or Aedes spp. mos-
quitoes display more rapid infection kinetics, enhanced viraemia and accelerated 
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neuroinvasion compared with mice inoculated with WNV but not subjected to mosquito 
bites (Schneider BS., et al., 2006; Steyer LM., et al., 2011). While numerous proteins in the 
saliva of hematophagous insects have been described, many remain that have not been 
characterized, especially with respect to viral infection. In addition, mosquito saliva causes 
dysregulation of local immune responses, including alterations in cytokine levels, leading to 
local immunosuppression and reduced recruitment of neutrophils, dendritic cells (DCs) and 
T cells to the primary site of infection (Schneider BS. and Higgs., 2008; Schneider BS., et 
al., 2010). Host skin acts as an important barrier to many infections, though WNV antigen 
has been detected in skin at multiple phases of infection. WNV replication was observed in 
skin tissue at the inoculation site at 1 and 3 days post-infection (Schneider BS., et al., 2006), 
and WNV has also been shown to spread to areas of skin contralateral to the site of 
inoculation (Brown AN., et al., 2007). Infectious WNV has been shown to persist in skin at 
the inoculation site for at least 14 days post-infection (Appler KK., et al., 2010).  
The early phase is defined by WNV replication in keratinocytes (Lim PY., et al., 2011) and 
skin-resident DCs, which can include dermal DCs and Langerhans cells 
(MHCCII+/NLDC1145+/E-cadherin+ cells) (Johnston LJ., et al., 2000) at the site of 
inoculation. Many reports document that both keratinocytes and fibroblasts are permissive to 
WNV infection in vitro and in vivo (Jarman RV., et al., 1968; Rezepova AI., et al., 1971; 
Kurane I. et al., 1992; Douglas MW., et al., 1994; Shen J. et al., 1995; Arnold SJ., et al., 
2004, Cheng Y., et al., 2004; Cheng Y., et al., 2004; Fredericksen BL., et al., 2004; 
Fredericksen BL., et al., 2006; Kajaste-Rudnitski A., et al., 2006; Kajaste-Rudnitski A., et 
al., 2006; Scherbik SV., et al., 2007; Welte T., et al., 2009; Lazear HM., et al., 2011; Lim 
PY., et al., 2011). This is followed by traffic of activated dendritic cells to the draining 
lymph node  (Johnston LJ., et al., 2000; Byrne S., et al., 2001) where the virus replicates 
further, antigen processing begins, and the early immune response may become evident 
(Kramer LD., 2008). Virus enters the blood stream by way of the efferent lymphatics and 
thoracic duct, which results in a viraemia that spreads the virus to the visceral organs of the 
body, including the spleen, heart, liver, kidneys and, possibly facilitates virus crossing the 
blood-brain barrier (BBB) resulting in CNS invasion and inflammation of the medulla, brain 
stem and spinal cord (Samuel MA. and Diamond MS., 2006). The specific target cells for 
WNV infection in the spleen and other peripheral tissues are not well defined, but are 
thought to be subsets of DCs, macrophages and possibly neutrophils (Ben-Nathan D., et al., 
1996; Samuel MA., et al., 2006; Bai F., et al., 2010).  
! 39!
Figure 11. Pathogenesis of West Nile 
virus in humans. A schematic of West 
Nile virus (WNV) pathogenesis in 
humans is shown, created on the basis of 
mouse models. Following a subcutaneous 
bite of a mosquito, WNV is thought to 
replicate in keratinocytes (Lim PY., et al., 
2011) and skin-resident dermal dendritic 
cells (DCs) and Langerhans cells. 
Infected DCs migrate to the regional 
draining lymph node and seed the virus 
within this node (Johnston LJ., et al., 
2000). Replication within the draining 
lymph node leads to viraemia and 
subsequent infection of peripheral organs, 
including reasonably permissive tissues 
(such as the spleen) and non-permissive 
tissues (such as the kidney and liver). By 
day 4, viral replication peaks in the spleen 
and serum. Between day 6 and day 8 after 
infection, WNV is cleared from 
peripheral organs, and infectious virus is 
detected within the brain and spinal cord, 
in part owing to the virus crossing the 
blood–brain barrier. This is achieved by 
increasing endothelial cell permeability 
(through the secretion of tumour necrosis 
factor (TNF)), by the breakdown of endothelial cell junctions (through the action of matrix 
metalloproteinases (MMPs)) or through a ‘Trojan Horse’ mechanism, whereby the virus is 
transported to the central nervous system (CNS) by infected immune cells. In the CNS, 
WNV infects and causes injury to neurons within the brain stem, hippocampus, cortex, 
cerebellum and spinal cord (Suthar SM., et al., 2013). 
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3.7.3 NEUROINVASION  
WNV is both neuroinvasive and neurotropic and invasion of the CNS tissues constitutes the 
third phase, where the virus targets and replicates in neuronal subsets. To establish infection 
in neurons of the brain, WNV first must cross the BBB. The BBB is highly regulated 
interface between the blood and the brain and is composed of four main cellular 
components: endothelial cells and their basement membrane (composed of collagen IV, 
laminin, proteoglycans, and glycoproteins); astrocyte and their food processes; microglial 
cells and pericytes (PCs) (Pardridge WM., 1983). The endothelium is the first line of defense 
against viral neuroinvasion: the tight junctions between endothelial cells form a diffusion 
barrier that restricts the entry of pathogens, immune cells, and immune mediators into the 
brain, thus preventing infection and limiting the potential side effects of immune system 
activation on generally non-renewable neurons (Ballabh P., et al., 2004; Muldoon LL., et al., 
2013). Endothelial models have been developed to study the mechanism of WNV 
translocation across BBB in vitro, and mechanisms proposed include: transcellular transport 
of virions across the infected endothelial cells and an increased permeability of the BBB, 
which can then facilitate a paracellular entry of WNV into the CNS parenchyma (Suen 
WW., et al., 2014). In any case, the mechanisms by which the virus gains entry to the CNS 
remains poorly understood, an over-represention of in vitro studies without adequate in vivo 
validation continues to obscure our understanding of the mechanism(s). (Beasley DW., et al., 
2002). The mechanism by which WNV and other encephalitic flavivirus cross the BBB may 
depend on the infection route and the pathogenicity of the WNV strain. Several models have 
been proposed for WNV entry into CNS (Fig. 12):  
1. Crossing of the BBB likely occurs through a hematogenous route: as viremia develops 
following peripheral replication locally at the site of virus inoculation and/or in the 
draining lymph nodes, both resulting in systemic dissemination of the virus. According to 
current literature, increased viral burden in the serum correlates with greater and more 
rapid WNV entry into the CNS (Johnson RT., et al., 1968; Johnson RT., et al., 1968) and 
for this reason the hypothesis of hematogenous dissemination of WNV into the CNS has 
been a common focus of investigation; 
2. Viral entry via passive diffusion as cell-free virions as result of blood-brain barrier (BBB) 
breakdown. The hypothesis of viral entry into CNS across by a more permeable BBB 
may due to intravascular levels of pro-inflammatory cytokine, which are produced during 
peripheral immune response that can mediate increased vascular permeability, also may 
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allow WNV to cross the BBB and infect neurons (Diamond MS., et at., 2003). WNV 
infection in peripheral tissue induces toll-like receptor (TLR)-3-mediated secretion of 
pro-inflammatory cytokines, including IL1β, IL-6, IL8 and TNF-α (Wang T., et al., 
2004), which may disrupt the BBB. Secreted TNF-α can modulate BBB permeability by 
altering endothelial cell tight junctions which may allow WNV to cross the BBB and 
infect neurons (De Vries HE., et al., 1996; Fiala M., et al., 1997; Wang T., et al., 2004). 
Semaphorin 7A upregulation after WNV infection also is linked to increased TNF-α 
production. Mice lacking Semaphorin 7A showed reduced TNF-α levels in serum, less 
BBB permeability, and reduced viral entry into the brain (Sultana H., et al., 2012). The 
flux of WNV into CNS can be also enhanced through degrading the tight junction 
proteins of the BBB extracellular matrix by activation of matrix metalloproteinases 
(Wang P., et al., 2008). In BBB model studies in vitro, treatment with inhibitors of matrix 
metalloproteinases prevented the disruption of tight junction integrity associated with 
WNV infection (Verma S., et al., 2010).  
3. The ‘Trojan Horse’ mechanism, via infected inflammatory cells: WNV is transported by 
infected immune cells (e.g., neutrophils or CD4+ or CD8+ T cells) across paracellular 
junction between endothelial cells into the brain parenchyma (Garcia-Tapia D., et al., 
2006; Wang S., et al., 2008). The ‘Trojan Horse’ hypothesis, as proposed in many 
reviews (Lim SM., et al., 2011; Sips GJ., et al., 2012; Suthar MS., et al., 2013): Garcia-
Tapia et al. (Garcia-Tapia D., et al., 2006) suggested that WNV infected Langerhan cells 
migrated from the site of inoculation to draining lymph node, where infection could then 
be relayed to mononuclear cells, such as monocytes and certain subsets of CD4+ 
lymphocytes. As hypothesized from a later study, Garcia-Tapia et al. (2007) suggested 
that the expression of lymphocyte and monocyte chemoattractants, such as IP-10 
(CXCL10) and MCP-5 (CCL12), respectively, in WNV infected brains, post-footpad 
inoculation, could recruit peripheral mononuclear cells into the perivascular space in the 
CNS. Here, the recruited leukocytes could produce pro-inflammatory cytokines, such as 
TNF-α and interleukins, which as mentioned above, could compromise the BBB integrity 
(Wang T., et al., 2004; Garcia-Tapia D., et al., 2007). Infected monocytes/macrophages 
and CD4+ lymphocytes could also facilitate productive viral replication in this region 
(Garcia-Tapia D., et al., 2006; Rios M., et al., 2006), providing a source of infection for 
brain microvascular endothelial cells, which in turn may exacerbate the BBB 
permeabilization via the degradation of inter-endothelial tight junctions and upregulation 
of CAM expression (Dai J., et al., 2008; Verma S., et al., 2009). Increased expression of 
! 42!
ICAM-1 has been detected before WNV entry into brain and may plays an important role 
in virus neuroinvasion in vivo (King NJ., et al., 2003). Dai et al., (2008) showed that 
ICAM-1 knock-out (KO) mice had increased survival rates that were associated with 
significantly lower virus burdens and significantly fewer brain lesions, as well as 
decreased BBB leakage, following a lethal WNV challenge (Dai J., et al., 2008). These 
latter results, put in the context of other studies (Drevets, D.A.; Leenen, P.J., 2000; 
Hubbard AK., et al., 2000; Greenwood J., et al., 2002), suggest that ICAM-1 acts both as 
a ligand for leukocyte receptors at the surface of the BBB endothelium and as a signal 
transducer that influences BBB permeability and the neuroinflammation process, thus 
facilitating the transmigration of infected leukocytes (Donadieu E., et al., 2013). Further 
recruitment, margination and transmigration of infected leukocytes across the paracellular 
junction of the BBB could result in viral neuroinvasion and dissemination (Garcia-Tapia 
et al. 2008).  
4. In some cases, WNV may penetrate into CNS through a transneural route and two 
neuroanatomical areas have been hypothesized to be involved in this mechanism: from 
the peripheral somatic nerves or from the olfactory nerves into the CNS (King NJ., et al., 
2007; Murray KO., et al., 2010; Cho H. and Diamond MS., 2012). Peripheral neurons are 
susceptible to infection by WNV (Monath TP., et al., 1983; Hunsperger EA., et al., 2006) 
and investigators have shown that through direct injection of WNV into the sciatic nerve 
transneural spread of the virus from the peripheral nervous system (PNS) to the CNS 
could be a putative route for neuroinvasion (Samuel MA., et al., 2007; Wang H., et al., 
2009). This study has specifically noted that WNV appeared to travel preferentially up 
motor nerves rather than sensor nerves. In addition, through compartmentalized neuron 
methods, has been demonstrated in hamsters that bidirectional axonal spread of WNV 
was possible (Samuel MA., et al., 2007). Retrograde axonal transport can bring WNV 
into CNS and accounts for acute limb paralysis, while anterograde transport would 
facilitate WNV spread in the CNS (Donadieu E., et al., 2013). Additional proposed 
mechanisms of CNS entry, as evident in a few in vivo challenge studies using neurotropic 
flaviviruses inoculated by either an intraperitoneal (Monath TP., et al., 1983), 
subcutaneous (foodpad) (Brown AN., et al., 2007) or intranasal route, include infection of 
olfactory neurons and rostral spread from the olfactory bulb (Brown AN., et al., 2007). 
5. Other possible entry mechanisms for WNV include infection or passive transport through 
choroid plexus epithelial cells that has been documented in animal models (Kramer-
Hämmerle, S., et al., 2005) or direct infection of brain microvascular endothelial cells 
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(Verma S., et al., 2009).  
Drawing together the conclusions from the above in vivo and in vitro studies, the route of 
WNV neuroinvasion may be much more complex than one distinct path from the 
peripheral site of inoculation to the CNS and WNV may enter the brain though a 
combination of mechanisms. Although the precise mechanism(s) of WNV entry into the 
CNS in humans requires further study, it may differ depending on the route of infection 
and the pathogenicity of the WNV strain. (Beasley DWJ., 2002; Diamond MS., et al., 
2009; Suen WW., et al., 2014). 
 
 
 
 
 
 
 
 
Figure 12. West Nile virus Neuroinvasive Mechanism. Potential mechanisms for 
neuroinvasion of West Nile virus include (1) direct infection of the vascular endothelium and 
subsequent entry to the central nervous system, (2) viral passage through the vascular 
endothelium due to disruption of the blood-brain barrier integrity by vasoactive cytokines, 
(3) a Trojan horse mechanism through which infected monocytes are trafficked into the 
central nervous system, or (4) retrograde axonal transport to the central nervous system 
following infection of peripheral neurons (Petersen LR., et al., 2013). 
Upon CNS entry, WNV infects and injures several different neuronal cell populations, 
including those in the cerebral cortex, brain stem hippocampus, and spinal cord (Eldadah 
AH. and Nathanson N., 1967; Xiao SY., et al., 2001; Diamond MS., et al., 2003a; Omalu 
BI., et al., 2003; Shrestha B., et al., 2003; Fratkin JD., et al., 2004). Later in the course of 
infection, the virus induces inflammatory lesions and neuronal infection that comprises 
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degeneration, loss of cell architecture, and cell death, but the mechanism by which WNV 
induces neuronal injury is still unclear (Donadieu E., et al., 2013). Indeed, although neuronal 
injury may be directly caused by viral infection, it may also results from indirect 
mechanisms by leukocyte infiltration and the host inflammatory response (Chambers TJ., et 
al., 2003): mononuclear cells infiltrate appear diffusely throughout infected regions, but it is 
not clear whether these inflammatory cells eradicate infection or contribute to pathogenesis 
by destroying infected neurons and releasing pro-inflammatory cytokines (Lazear HM., et 
al., 2011). Elucidating WNV neuroinvasion in humans has proved to be difficult because 
WNV strains demonstrate variable virulence in mammals. However, animal models of WNV 
infection have provided insights into the pathogenesis of WNV in mammals to identify viral 
and host factors that control the viral dissemination and entry into the CNS (Donadieu E., et 
al., 2013).  
3.8 TROPISM 
WNV is transmitted to vertebrates by the bite of an infected mosquito, which deposits high 
doses of virus extravascularity in the skin (Styer LM., et al., 2007). The in vivo cell targets 
of WNV in the skin are unknown; however, it is believed that WNV infects Langerhan cells 
(LCs), the resident dendritic cells (DCs) of the skin and keratinocytes (Lim PY., et al., 
2011). In fact, LCs are in vivo cell targets of another flavivirus, dengue virus (Wu SJ., et al., 
2000), and DCs are susceptible to infection by WNV in vitro (Davis CW., et al., 2006; Silva 
MC., et al., 2007; Martina BE., et al., 2008; Lim PY., et al., 2010). Moreover, WNV RNA 
persists in the skin for up to 4 months post-inoculation (Appler KK., et al., 2010) and these 
results suggesting that WNV infects nonmigrating cells in the skin, likely keratinocytes, may 
contribute to WNV persistence in the skin (Lim PY., et al., 2011). Following WNV 
inoculation of mice, LCs migrate from the skin at the inoculation site to the draining lymph 
nodes (DLN) (Johnston LJ., et al., 2000). On the other hand, initial WNV replication after 
mosquito transmission or subcutaneous inoculation occurs in both the DLN and the skin 
(Brown AN., et al., 2007; Styer LM., et al., 2011), suggesting that, in addition to cells in the 
skin, lymph node are also productively infected, resulting in a primary viremia. WNV then 
spreads systemically to visceral organs, such as spleen, where takes place a second round of 
replication, presumably in epithelium cells and macrophages, respectively (Rios M., et al., 
2006). Generally, WNV replication is typically restricted to the skin, draining lymph node, 
spleen, and CNS in humans and wild-type mice (Samuel MA. and Diamond MS., 2006; Lim 
PY., et al., 2011). Low levels of infectious virus can be recovered from the lung, kidney, 
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heart, pancreas and other peripheral tissues but not the liver, of wild-type infected mice 
(Brown AN., et al., 2007). Most peripheral organs, including the liver, are not typically 
associated with WNV replication in humans. However, reported cases of kidney, liver, and 
heart organ transplant-transmitted WNV infections have been described with outcomes 
ranging from asymptomatic infections to death in the recipients (Rhee C., et al., 2011). 
These clinical observations suggest that peripheral organs in humans are also capable of 
being infected by WNV but infection is restricted or controlled by immune defense 
programs. However, following WNV spreads to the spleen, where the virus is amplified, and 
a secondary viremia, WNV can cross the BBB and invade the central nervous system tissues. 
Regardless of how WNV enters the central nervous system, into the brain the virus must 
propagate efficiently within target cells to cause meningo-encephalitis. Studies in humans 
and mice have demonstrated that neurons are the primary cells targeted by WNV 
(Fredericksen BL., 2014). In humans, WNV is most often detected in neurons in the cerebral 
cortex, thalamus, brainstem, basal ganglia, cerebellar Purkinje cells, and spinal cord (mainly 
anterior horn), and in some cases, infection has been detected in the olfactory bulb and 
hippocampus (Fig. 13). WNV has been detected in the same regions of the brain of 
experimentally infected mice as in humans, indicating a similar tropism of WNV in humans 
and animal models (Xiao SY., et al., 2001; Omalu B., et al., 2003; Shrestha B., et al., 2003; 
Lim SM., et al., 2011). Moreover, WNV-positive brain microvascular endothelial cells and 
astrocytes have been detected in birds and humans, respectively, suggesting that these cells 
may serves as secondary targets in vivo (Lopes H., et al., 2007; Van Marle G., et al., 2007; 
Wunschmann A., et al., 2004). Astrocytes and endothelial cells form with neurons the 
neurovascular unit (NVU) and functions to regulate blood flow, the integrity of the BBB, 
and neuronal activity in response to environmental changes (Fredericksen BL., 2014). In 
vitro studies conducted at both low and high MOIs, demonstrated that pathogenic strains of 
WNV replicate within all NVU cell types, though replication in astrocytes was the most 
restricted (Cheeran MC., et al., 2005; Diniz JA., et al., 2006; Hussmann et al., 2013; van 
Marle G., et al., 2007; Verma S., et al., 2010). Moreover, although with several differences, 
neurons and astrocytes were found to support productive WNV infection, whereas viral 
growth was poorly permissive in microglial cells (Cheeran MCJ., et al., 2005). Mechanisms 
for this selective tropism among neuronal populations remain to be elucidated. Domain III of 
the envelope glycoprotein of WNV has been implicated in neuroinvasiveness, which 
constitutes the receptor-binding domain, and seems to be a primary virulence factor, but 
putative receptors on neuronal target cells have not yet been identified (Granwehr BP., et al., 
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2004). Moreover, animal studies using intracranial inoculation indicate that most, if not all, 
strains of WNV can replicate within the CNS; nonetheless, the extent of neurovirulence is 
strain-dependent (Beasley DW., et al. 2002a; Shrestha et al. 2008). Recent studies have 
begun to define the host determinants for susceptibility to WNV in the various cell types 
comprising the neurons, endothelial and astrocytes cells and the viral factors responsible for 
the strain-dependent differences in neuropathogenicity (Beasley DW., et al. 2004; Beasley 
DW., et al. 2005; Cho et al. 2013; Hussmann et al. 2013; Shirato et al. 2004). Examination 
of WNV replication within the cells types comprising the neurons, endothelial and astrocytes 
cells infected at low MOIs demonstrated that high and low neuropathogenic strains of WNV 
replicate with similar kinetics and to equivalent levels in brain microvascular endothelial 
cells and neurons (Hussmann et al. 2013). However, astrocytes exhibited a reduced 
susceptibility to the low neuropathogenic strain compared to the high neuropathogenic 
strain, suggesting a possible role for this cell type in limiting WNV replication within the 
CNS.  
 
 
 
 
 
 
 
 
 
Figure 13. Frequency of infection of several regions of the human brain by West Nile 
virus. The areas most often infected by WNV include: the cerebral cortex, thalamus, basal 
ganglia, brainstem, cerebellum, and spinal cord (anterior horn) (indicated in dark red). 
Infection has less frequently been found in the olfactory bulb and hippocampus (indicated in 
orange) (Lim SM., et al., 2011). 
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3.9 CLINICAL MANIFESTATIONS IN HUMANS 
WNV infection in humans causes a spectrum of manifestations from subclinical infection to 
death (Petersen and Marfin 2002). It is generally estimated that the majority (75 to 80%) of 
WNV infections in humans are asymptomatic. Of those who develop symptoms, 
approximately 20% of the infected people, develop an acute, systemic febrile illness, termed 
WN fever (WNF), and less than 1% of the symptomatic cases develop neurologic illness, 
which is primarily attributed to the neuroinvasive disease, where the virus breaches the 
intrathecal space and produces infection of CNS structures (Sejvar JJ., et al., 2003). West 
Nile Neuroinvasive disease (WNND) includes: aseptic meningitis (West Nile meningitis, 
WNM) that involves infection of the meninges (the outer covering of the brain and spinal 
cord) and makes up the largest percentage of the neuroinvasive disease in younger age 
groups; encephalitis (West Nile encephalitis, WNE) that involves viral infection of the brain 
parenchyma itself and is more typically manifested in older persons or immunocompromised 
individuals; acute poliomyelitis-like syndrome (West Nile poliomyelitis, WNP) that results 
from viral infection of the anterior horn cells of the spinal cord, leading to acute flaccid limb 
weakness (Campbell GL., et al., 2002; Granwehr BP., et al., 2004; Sejvar JJ., 2014). 
Overall, only 1 in 150 infections results in the most severe and potentially lethal form of the 
disease, although the relative risk is increased in the elderly or individuals with 
compromised immune systems (Sejvar JJ., 2007; De Filette M., et al., 2012). The incubation 
period for clinical illness generally ranges from 2 to 14 days after infection by mosquito bite, 
but prolonged incubation periods of up to 21 days have been observed among 
immunocompromised patients (Pealer LN., et al., 2003; Rhee C., et al., 2011).  
3.9.1 WEST NILE FEVER (WNF) 
WNF is the predominant clinical syndrome seen in most WNV infected persons that develop 
symptoms. All ages may be affected, but data suggest that the proportion of WNF may be 
higher among younger individuals (Pepperell C., et al., 2003, Brown J., 2004; O’Leary DR., 
et al., 2004; Hayes EB. and Gubler DJ., 2005). WNF can range from a mild infirmity lasting 
few days to a debilitating illness lasting weeks to months, and in some instances, they can 
result in hospitalization (Petersen LR., et al., 2013). Following an incubation period of 
approximately 2-14 days, infected persons typically begins with sudden onset of fever 
(usually >39°C), headache, fatigue, myalgia, often accompanied by gastrointestinal 
complaints, including nausea and vomiting that may lead to dehydration (Cambpell GL., et 
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al., 2002; Sejvar JJ., 2014). WNF may sometimes be associated with a rash that may be 
transient, lasting less than 24h in some persons, and tends to be morbilliform, 
maculopapular, and nonpruritic. The rash predominates over the torso and extremities, 
sparing the palms and soles and interestingly appears to be more frequently observed among 
younger persons than among older persons (Ferguson DD., et al., 2005). Although elderly 
persons with WNF may experience adverse outcomes and have a higher mortality rate than 
younger symptomatic persons, most patients experience complete recovery (Emig M. and 
Apple DJ., 2004; O’Leary DR., et al., 2004). However, some otherwise healthy persons may 
continue to experience a prolonged fatigue, headaches and difficulties concentrating for days 
or weeks following infection (Watson JT., et al., 2004). Deaths among persons with WNF 
occur primarily among older persons and among individuals with compromised immune 
systems and this is frequently attributable to cardiopulmonary complications (Sejvar JJ., et 
al., 2011). 
 
3.9.2 WEST NILE NEUROINVASIVE DISEASE (WNND) 
Approximately 5% of patients with symptomatic WNV infection develop neurologic disease. 
Severe WNND is associated with neurological involvement that varies from meningitis 
and/or encephalitis, to ocular manifestations, to poliomyelitis-like condition with acute 
flaccid paralysis that can result in respiratory failure (Campbell GL., et al., 2002).  
West Nile meningitis (WNM), similar to that of other viral meningitides, is characterized by 
abrupt onset of fever and headache along with meningeal signs and photophobia. Headache 
may be severe, requiring hospitalization for pain control, and associated gastrointestinal 
disturbance such as nausea, vomiting and diarrhea, may result in dehydration (Sejvar JJ., et 
al., 2008). WNM, in cases that do not progress to meningoencephalitis, is generally 
associated with a favorable outcome and the fatality rate is low (Ceausu E., et al., 1997). 
Although, similar to WNF, some patients experience persistent headache, fatigue and 
myalgia (Sejvar JJ., et al., 2003; Sejvar JJ., et al., 2008).  
Clinically, West Nile encephalitis (WNE) is generally typical of the arboviral encephalitides. 
WNE ranges in severity from a mild, self-limited confusional state to severe encephalopathy, 
coma and death: a prodrome of fever, headache, and other non-specific symptoms (i.e. 
typical WNF) lasting from 1 to few days occurs in some patients; while in others, a more 
abrupt onset of fever accompanied by symptoms and signs of encephalitis, especially mental 
status changes and vomiting, has been described and in about 15% of cases, cerebral 
dysfunction progress to coma. This manifestation is more commonly seen in older 
! 49!
individuals, particularly over the age of 55, as well as among organ transplant recipiens 
(Armali Z., et al., 2003; Kumar D., Prasad GV., et al., 2004; O’Leary DR., et al., 2004; 
Ravindra KV., et al., 2004). Whether other immunocompromised patients are at higher risk 
remains unclear, but severe WNV disease has been described in persons with malignancies 
(Guarner J., et al., 2004). Several neurological syndromes, primarily extrapyramidal 
(Pepperell C., et al., 2003; Sayao AL., et al., 2003; Sejvar JJ., et al., 2003; Burton JM., et al., 
2004) and movement disorders, including severe tremors and parkinsonism, are frequently 
observed in patients with WNE (Hayes EB., et al., 2005; Robinson RL., et al., 2003; Sejvar 
JJ., et al., 2003). Indeed, patients with West Nile encephalitis frequently develop a coarse 
tremor, particularly in the upper extremities. The tremor tends to be postural and may have a 
kinetic component (Sejvar JJ., et al., 2003; Sayao AL., et al., 2003; Burton JM., et al., 
2004). Myoclonus, predominantly of the upper extremities and facial muscles, may occur 
and may be present during sleep. Cerebellar ataxia, increased intracranial pressure, cerebral 
edema, and seizures have been described but are uncommon (Burton JM., et al., 2004; Sayao 
AL., et al., 2003; Kanagarajan K., et al., 2003). These movement disorders usually follow 
the onset of mental status changes and typically resolve over time. However, tremor and 
parkinsonism may persist in patients recovering from severe encephalitis (Sejvar JJ., et al., 
2003; Pepperell C., et al., 2003). Up to 1 year may be necessary for convalescence following 
encephalitis. Analysis of the long-term outcomes of WNND has estimated that myalgia, 
confusion and lightheadedness may persist even beyond this period and prolonged 
depression persists in as many as 31% of patients (Sejvar JJ., 2007; Murray K., et al., 2010). 
Clinical features in patients with WNM or WNE are usually familiar to many physicians and 
prompt them to search for a viral cause. However, acute flaccid paralysis may not be familiar 
to some clinicians, particularly when it occurs in the absence of meningitis or encephalitic 
signs and symptoms, resulting in difficulties for an accurate diagnosis (Li J., et al., 2003; 
Kramer LD., et al., 2007). In the 1999 New York City outbreak, about 10% of the 
hospitalised patients had acute flaccid paralysis (Li J., et al., 2003). However, the underlying 
cause (poliomyelitis) for this acute paralysis was not recognised until 2002 (CDC 2002; 
Glass JD., et al., 2002; Leis AA., et al., 2002). Acute and abrupt onset of limb weakness 
may be associated in WNV infection. In most cases, this limb paresis (partial weakness) or 
paralysis (complete loss of muscle power) is due to viral involvement of the anterior horn 
cells of the spinal cord, resulting in anterior (polio) myelitis (Glass JD., et al., 2002; Leis 
AA., et al., 2002; Jeha LE., et al., 2003; Sejvar JJ., Leis AA; et al., 2003; Sejvar JJ., et al., 
2005). The clinical features of West Nile Poliomyelitis (WNP) are characteristic and 
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generally dramatic, allowing for differentiation from the characteristic diffuse “muscle 
weakness” described by many persons with severe fatigue associated with WNV infection 
(Sejvar JJ., et al., 2014). WNP generally develops soon after illness onset: asymmetric 
weakness usually develops rapidly within the first 48 hours after symptom onset, although 
patients with extensive spinal cord involvement develop a more symmetric dense 
quadriplegia. Central facial weakness, frequently bilateral, can also occur (Jeha LE., et al., 
2003). Sensory loss or numbness is generally absent, though some patients experience 
intense pain in the affected limbs just before or during the onset of weakness (Sejvar JJ., et 
al., 2005). The most severe manifestation of WNP is the involvement of respiratory muscle 
innervation that leads to diaphragmatic and intercostal muscle paralysis and resulting in 
respiratory failure and requiring emergent endotracheal intubation. Respiratory involvement 
in WNP is associated with high morbidity and mortality, and among survivors, prolonged 
ventilatory support lasting months may be required (Sejvar JJ., et al., 2005). However, in 
some cases, patients are unable to be weaned from mechanical ventilation, and the 
withdrawal of ventilator support leads to death (Sejvar JJ., et al., 2014). Other forms of 
Acute flaccid paralysis (AFP) associated with West Nile virus infection include Guillain-
Barré syndrome (GBS) and other demyelinating neuropathies, motor axonopathy, axonal 
polyneuropathy, involvement of ventral spinal roots, myasthenia gravis, and brachial 
plexopathies (Leis AA. and Stokic DS., 2012). The weakness associated with GBS is usually 
symmetric, ascending (e. g. beginning in the legs and subsequently involving arms and 
cranial nerve innervates muscles, and is associated with sensory and autonomic dysfunction. 
Other manifestations have been described in the setting of West Nile virus infection include 
multifocal choroiditis, vitritis, myocarditis, pancreatitis, fulminant hepatitis, rhabdomyolysis, 
stiff-person syndrome, and autonomic instability (Southam CM. and Moore AE., 1952; 
Parelman A. and Stern J., 1974; McIntosh BM., et al., 1976; Petersen LR., et al., 2012). 
However, after fever and neuroinvasive disease, chorioretinitis and vitris are the most 
commonly reported clinical manifestation of WNV infection (Adelman RA., et al., 2003; 
Bains HS., et al., 2003; Kuchtey RW., et al., 2003; Hershberger VS., et al., 2003; 
Vandenbelt S., et al., 2003; Shaikh S., et al., 2004). Chorioretinal lesions have been 
described as multifocal and with a “target-like” appearance and have also been noted retinal 
hemorrhages. Lesions tends to be clustered primarily in the temporal and nasal regions of the 
periphery of the fundus and this distribution and appearance of the chorioretinal lesions have 
been proposed that may be distinctive for WNV infection (Hershberger VS., et al., 2003). 
An inflammatory vitritis has occurred concomitantly with the chorioretinitis and may be 
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significant enough to obscure the optic disc. Symptomatic persons describe gradual visual 
blurring and loss, floaters and flashes (Sejvar JJ., 2014).  
Numerous other clinical manifestations have been described in association with WNV 
infection, but these are rare manifestations and a definitive association with WNV infection 
is difficult to substantiate. These rare extraneurological manifestations include: 1. 
Rhabdomyolysis, that has been temporally associated with WNV infection suggesting a viral 
myositis, although the presence of virus in muscle tissue has not been observed (Kulstad 
EB., et al., 2003; Jeha LE., et al., 2003); 2. Pancreatitis and fulminant hepatitis that have 
been reported in case of severe WNV infection (Perelman A., et al., 1974; Sampson BA,. et 
al., 2000). In this case, WNV has been identified in hepatic and pancreatic specimens at 
pathology, suggesting that viscerotropic WNV disease may be an infrequent manifestation of 
infection; 3. Myocarditis and cardiac arrhythmias: the first has been seen pathologically in 
WNV infection and the second has occurred in individuals with WNP, suspected to be due to 
autonomic dysfunction (Fratkin JD., et al., 2004); 4. Moreover, in some cases convalescent 
patients may have persistent or chronic infection detected through PCR of the urine, which 
suggested ongoing viral replication in renal tissue (Murray K., et al., 2010; Murray KO., et 
al., 2011). Although persistence of WNV has also been noted in several animals models 
(Pogodina VV., et al., 1983; Tesh RB., et al., 2005; Siddharthan V., et al., 2009), it has not 
been uniformly evident in assays of urine (Gibney KB., et al., 2011).  
 
3.9.3 HOST RISK FACTORS  
Overall, among all individuals who become infected, approximately 25% develop WNF 
(Zou S., et al., 2010) and only 1 in 150 to 250 develops WNV neuroinvasive disease WNND 
(Mostashari F., et al., 2001; Petersen LR., et al., 2012). Infections in humans are 
predominantly subclinical, but reported infection manifestations may range from fever and 
myalgias to meningoencephalitis and death (Petersen LR. and Marfin AA., 2002). Several 
factors influence the outcome of WNV infection in the human and animal hosts including 
virus strain, age, immune status, and genetic susceptibility. The most important risk factor 
for acquiring WNV infection is exposure to infected mosquitoes. An analysis of the 
locations of WNV disease cases during the 1999 outbreak in New York found that cases 
were clustered in an area with higher vegetation cover, indicating favorable mosquito habitat 
(Brownstein JS., et al., 2002). Risk factors for developing WNF following infection are 
poorly defined. A follow-up study of asymptomatic, viremic blood donors indicated that 
increasing viral load and female sex, but not age, subsequently increased the risk of 
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developing WNF (Zou S., et al., 2010). A smaller follow-up study of viremic blood donors 
suggested that younger persons were more likely to develop WNF (Brown JA., et al., 2007). 
In contrast, elderly and immunocompromised individuals are more susceptible to develop a 
neuroinvasive disease (WNND), particularly encephalitis (Lindsey NP., et al., 2010; Carson 
PJ., et al., 2012) that may result in death. Surveillance data from the US indicate that age is 
the most important host risk factor for the development of WNND after infection. Indeed, 
although neuroinvasive disease of WNV infection has been reported among all ages, the 
proportion of individuals who progress to WNND is greater among older compared to 
younger persons. It has been estimated that the incidence of neuroinvasive disease increases 
approximately 1.5-fold for each decade of life, resulting in a 20-fold increased risk of 
neuroinvasive disease and death among individuals over 50 years of age and 30 times greater 
for persons 80-90 years old compared to children younger than 10 years old, the case-fatality 
rate ranges from 15% to 29% (Chowers MY., et al., 2001; Nash D., et al., 2001; Petersen 
LR. and Marfin AA., 2002; O’Leary DR., et al., 2004). Among those older adults who 
survive, as many as 50% may have significant postillness morbidity for at least a year 
following infection (Campbell GL., et al., 2002) and may have an increased risk of death for 
up to 3 years after acute illness (Lindsey NP., et al., 2012). Some possible explanations for 
the higher incidence of WN meningoencephalitis in the elderly include factors that enhance 
viral entry into the CNS by disruption of the cerebral endothelium (e.g. hypertension, 
cerebrovascular disease) or an increase in the magnitude and duration of viremia (e.g. 
immunosuppression, immune senescence). Higher fatality is also seen in infected infants and 
immunocompromised patients (Granwehr BP., et al., 2004). Based upon a limited number of 
cases, persons infected through transplant of infected organs are likely at higher risk of 
developing neuroinvasive disease and death compared with patients infected through the 
natural route of mosquito bite inoculation (Rhee C., et al., 2011; Nett RJ., et al., 2012). 
However, conflicting data exist regarding risk of severe neurologic disease among other 
organ transplant recipients and may be related to the interval between infection via mosquito 
bite and transplantation or the type of post-transplant immunosuppresive therapy (Kumar D., 
et al., 2004; Freifeld AG., et al., 2010; Sejvar JJ., 2014). In addition to old age, 
immunosuppression, such as that of transplanted people or human immunodeficiency virus 
infected patients, a history of cancer, diabetes, alcohol abuse, a history of cardiovascular 
disease or chronic renal disease, hepatitis C infection and as well as male sex may increase 
the risk of neuroinvasive disease (Campbell GL., et al., 2002; Bonde AV., et al., 2003; 
Murray K., et al., 2006; Lindsey NP., et al., 2010; Sejvar JJ., et al., 2011; Carson PJ., et al., 
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2012; Cho H. and Diamond MS., 2012; Lindsey NP., et al., 2012).  
Given the fact that only a small minority of those infected develop severe disease and the 
fact that risk factors, apart from older age and immunosuppression, are not well defined, 
there is a strong rationale to suspect a genetic predisposition to WNV neurological 
complications: specific host genetic factors that influence the severity of infection with 
WNV and antiviral innate immune response have been identified (Table 2) (Loeb M., et al., 
2011; Colpitts TM., et al., 2012). Certain HLA types appear to be associated with risk of a 
more severe outcome (HLA-A*68 and C*08) or better resistance to infection (B*40 and 
C*03) (Lantieri MC., et al., 2011). Single nucleotide polymorphism (SNP) studies have 
detected SNPs in key regulators of immune function, including interferon pathway elements. 
In particular, an association of SNP between symptomatic and asymptomatic WNV 
infections and IRF3 and MX-1 innate immune response and effector genes has been reported 
(Bigham AW., et al., 2011). IRF3 encodes a member of the interferon regulatory 
transcription factor family involved in the upregulation of type 1 IFN genes as well as other 
pathway genes. However, IRF3 has been reported to protect mice from WNV-induced 
disease by both IFN-dependent and independent mechanisms (Daffis S., et al., 2001; 
Fredericksen BL., et al., 2004). After a peripheral WNV infection, irf3-/- mice exhibited 
increased mortality, early viral entry into CNS, and increased virus levels in the brain and 
spinal cord compared to wild-type mice (Daffis S., et al., 2001). For this reason IRF3 may a 
candidate for influencing the risk of symptomatic WNV infection in humans. Also MX1, 
that is a GTPase with antiviral functions and belongs to MX (myxovirus resistance) family 
of IFN-induced proteins, may have an effect on flavivirus infections in humans. Indeed, 
upon viral infection, a host cell secretes type 1 IFN that, in turn, induce the production of 
MX proteins that diminish viral replication. In mice, Mx1 confers resistance to 
orthomyxoviruses including influenza viruses, but has not been demonstrated to confer 
resistance to flaviviruses (Staeheli P., et al., 1988). Another study examined CCR5∆32, a 
relatively common 32-bp deletion in the coding region of the chemokine receptor 5 (CCR5), 
which is known to be protective in infection with HIV, that was initially reported to be 
associated with both increased susceptibility to WNV infection and death. A greater 
incidence (4.2%) of loss-of-function CCR5∆32 homozygotes was observed in symptomatic 
and lethal WNV cases compared to that in the general population (1.0%), suggesting that 
CCR5 may mediate resistance to WNV infection in humans (Glass WG., et al., 2006; Lim 
JK., et al., 2008). More recently, this association was not replicated, but results suggestive of 
a link to clinical manifestations of infection with CCR5∆32 mutation were reported (Lim 
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JK., et al., 2010). In certain mouse strains, susceptibility to flavivirus, including WNV, maps 
to a truncated isoform of the 2’-5’ oligoadenylate syntetase (OAS1b) gene: a member of an 
IFN-regulated gene family involved in degradation of viral RNA. Compared with the 
resistant mice, susceptible mice produce an OAS1b protein lacking 30% of the C-terminal 
sequence, resulting in the inactivation of the OAS/RNaseL pathway. Consequently, a large 
amount of virus is produced in the susceptible mice. A recent study suggests that allelic 
variants in two human ortholog genes, OAS1 and OASL, are associated with increased risk 
of WNV susceptibility or WNND, although subsequent attempts to replicate the association 
with OASL were unsuccessful (Yakub I., et al., 2005; Lim JK., et al., 2009). The products of 
OAS1, OAS2, OAS3, OASL, and their downstream effector RNaseL each influence host 
defense by blocking viral replication (Samuel CE., 2001). Thus, in humans, variation in 
OAS1 is a genetic risk factor for initial WNV infection although not for disease severity 
(Diamond MS., et al., 2009). Moreover, a dominant negative splice variant of RNase L, 
which functions in the antiproliferative roles of interferon, was detected more often in WNV 
patients than in control patients (Yakub I., et al., 2005). Thus genetic variation in the IFN 
response pathway appears to correlate with the risk of symptomatic WNV infection in 
humans. Another genomic study investigated >1.500 symptomatic subjects, with severe 
versus mild disease, and showed that SNPs in RFC1 (a replication factor), SCN1a (a sodium 
channel), and ANPEP (an aminopeptidase) genes have been associated with a more severe 
neurological disease, although even more differences might have been revealed when 
comparing asymptomatic and symptomatic cases (Loeb M., et al., 2011).  
 
Table 2. Genes and corresponding SNPs important in human WNV infection (Colpitts 
TM., et al., 2012). 
 
! 55!
3.9.4 VIRAL RISK FACTORS  
Several factors influence the outcome of WNV infection in the human, including viral 
factors. For example the capacity of WNV to infect several target cells and evade immune 
response allows WNV to survive and cause disease within the host (Table 3). Certain aspects 
of the biology of WNV facilitate its ability to cause severe disease. WNV productively 
infects diverse cell populations from many animal species, suggesting usage of multiple 
and/or well-conserved receptors (Xiao SY., et al., 2001; Banet-Noach CL., et al., 2003; 
Farajollanhi A., et al., 2003; Jacobson ER., et al., 2005; Root JJ., et al., 2005; Tesh RB., et 
al., 2005; Garcia-Tapia D., et al., 2006). The relatively diverse tropism of WNV allows viral 
replication in several tissues in animal and human hosts and may contribute to the wide 
spectrum of clinical manifestations (Sejvar JJ., et al., 2003; Yim R., et al., 2004; Hayes EB., 
Komar RS., et al., 2005; Paddock CD., et al., 2006). Moreover, WNV is cytolytic and 
induces apoptosis in a variety of cell types, including neurons (Parquet MC., et al., 2001; 
Shrestha B., et al., 2003). Although few studies have investigated the mechanisms of WNV-
induced cell death in vivo, individual WNV proteins may contribute to virus-mediated 
cytotoxicity. In vitro, expression of either NS3 or capsid protein induced rapid, caspase-
dependent apoptosis, and capsid protein expression in vivo resulted in cell death (Yang JS., 
et al., 2002; Ramanathan MP., et al., 2006). 
In addiction, genetic variation may affect WNV virulence (Samuel MA. and Diamond MS, 
2006). Sequence-based phylogenic analyses of global WNV strains have revealed two major 
lineages: lineage 1 and 2. Lineage 1 strains are detected worldwide and are commonly 
involved in human and equine outbreaks, including in Romania (1996), Russia (1999), Israel 
(1998 to 2000), and the Americas (1999 to 2005) (Dauphin G., et al., 2004; Mackenzie JS., 
et al., 2004). In contrast, lineage 2 strains appears to be localized to central and southern 
Africa and have caused only occasional human infections (Jupp PG., 2001; Lanciotti RS., et 
al., 2002). Generally, lineage 1 strains induce significant encephalitis and mortality in birds 
and mammals, although isolates from both lineages can be neuroinvasive (Samuel MA. and 
Diamond MS., 2006). Thus, while lineage 1 WNV isolates appear to be linked to the recent 
increase in severe infection of humans, pathogenic lineage 2 isolates have been identified 
and have the potential to induce significant human disease. The specific sequence 
determinants of virulence are an area of intensive study. N-linked glycosylation of the E 
protein appears important for neuroinvasion as mutations of E-protein glycosylation sites 
attenuated viral replication and pathogenesis (Beasley DW., et al., 2002; Shirato K., et al., 
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2004; Beasley DW., Whiteman MC., et al., 2005). Moreover, E-protein glycosylation 
modulates WNV virulence by altering virion stability, viral replication, and particle 
assembly (Beasley DW., Whiteman MC., et al., 2005; Hanna SL., et al., 2005;  Li J., et al., 
2006). Glycosylation of the NS1 protein has also been linked to WNV pathogenesis: WNV 
NS1 contains three N-linked glycosylation sites (residues 130, 175, and 203) and mutants 
lacking glycosylation at either two or three sites induced lower viremia and decreased 
lethality in vivo (Samuel MA. and Diamond MS., 2006).  
WNV has also evolved specific strategies to avoid and/or attenuate innate and adaptive 
immune responses. Flaviviruses, including WNV, are largely resistant to the antiviral effects 
of IFN once cellular infection is established. Through studies with WNV, and others 
flavivirus, this phenotype has been largely ascribed to the actions of non-structural proteins 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5. These non-structural proteins suppress host 
IFN-induced responses at multiple stages within the cell by delaying IRF-3 activation and 
IFN-α gene transcription and by preventing the phosphorylation and activation of JAK1 and 
Tyk2 (Muñoz-Jordan JL., et al., 2003; Lin RJ., et al., 2004; Best SM., 2005; Guo JT., et al., 
2005; Liu WJ., et al., 2005; Lin RJ., et al., 2006; Murray K., et al., 2006). The replication 
fitness and virulence of lineage 1 and lineage 2 strains has been linked to control of host IFN 
responses (Keller BC., et al., 2006): while a pathogenic lineage 1 Texas isolate actively 
antagonized IFN signalling, an attenuated lineage 2 strain from Madagascar lacked this 
activity. The replication and virulence of the lineage 2 isolate were restored in cells and mice 
that lacked the IFN-α/βR. These data suggest that inhibition of type I IFN responses may be 
a key feature in the evolution of pathogenic WNV strains. Consistent with this, an aminoacid 
substitution (Ala30Pro) in NS2A protein of Kunjin virus could reduce NS2A-mediated 
inhibition of the IFN response resulted in an attenuated neurovirulence (Liu WJ., et al., 
2006). Escape from the humoral immune response may also contribute to WNV 
pathogenesis. Flaviviruses have a low-fidelity RNA-dependent RNA polymerase that 
generates quasispecies in vivo (Jerzak G., et al., 2005). This antigenic variation may allow 
viral quasispecies to escape antibody-mediated neutralization (Beasley DW. and Barrett 
AD., 2002), as strains with mutations at the dominant neutralizing epitope in DIII of the E 
protein can emerge (Li L., et al., 2005). 
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TABLE 3. WNV virulence factors (Samuel MA. and Diamond MS., 2006). 
 
3.10 DIAGNOSIS 
Laboratory diagnosis relies on isolation of virus, detection of viral antigens or RNA in blood 
or tissues, or detection of virus-specific IgM antibody that should be further confirmed by 
detection of IgG antibody in the same or a subsequent sample (Fig. 14). 
 
 
 
 
 
 
 
 
Figure 14.  Schematic of virologic and serologic tests in West Nile virus encephalitis. 
Solid lines represent the more common results; broken lines represent reported ranges. The 
shaded box is an example of a typical patient (Kramer LD., 2008). 
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3.10.1 NUCLEIC ACID BASED TESTS FOR WNV  
The use of nucleic acid detection techniques has provided an opportunity to diagnose WNV 
in patients prior the production of specific IgM antibody, with the circulation of detectible 
levels of WNV RNA in blood, an average, 4 days prior to the first detection of IgM 
antibodies (Busch MP., et al., 2008).  WNV nucleic acid detection has become a routine test 
for screening blood products in endemic areas, and the introduction of such measures in 
these areas has essentially eliminated WNV acquisition through the donated blood or organ 
supply (Busch MP., et al., 2005). Several methods for detection of viral RNA have been 
applied for WNV surveillance and diagnosis, mainly reverse transcription polymerase chain 
reaction (RT-PCR) assays, quantitative real-time RT-PCR and nucleic acid sequenced-based 
amplification (Lanciotti RS., 2003). All these assays have been extensively used in mosquito 
pools, and animal and human samples (blood and/or CFS), although the latter are usually 
collected after the onset of clinical signs, when virus is unlikely to be present on them 
(Martin-Acebes MA., et al., 2012). 
3.10.2 SEROLOGIC DIAGNOSIS OF WNV INFECTIONS  
Serological testing remains the most widely used method for detection of anti-WNV 
antibodies in human and animal samples (Beasley DW., 2005a). Following exposure to 
WNV, both IgM and IgG antibodies are produced. In most cases, IgM antibodies can be 
detected within 4 to 7 days after the initial exposure and may persist in the serum for more 
than one year in some patients (Roehrig JT., et al., 2003; Colpitts TM., et al., 2012). In 
comparison, anti-WNV IgG are reliably detected approximately 8 days after the onset of 
symptoms and they have a limited use in the initial diagnosis of WNV infection (Tardei G., 
et al., 2000). The commercial IgM antibody capture enzyme-linked immunosorbent assay 
(MAC-ELISA) can be applied to both CSF and serum: the detection of IgM antibody in the 
CSF is indicative of infection of the CNS and in conjunction with evidence of neurological 
has been accepted as diagnostic of WNV disease; whereas the presence of IgM antibody in 
the serum alone is strongly suggestive of recent infection but not definitive due to 
persistence for al least 16 months (199 days in the CSF) in patients with WNND and to some 
cross-reactivity with antibody to other flaviviruses. Indeed, the main weakness that limits the 
clinical relevance of serological methods is the broad antigenic cross-reactivity that exists 
between related flavivirus (Japanese encephalitis virus, St. Louis encephalitis virus, Yellow 
fever virus, and Dengue virus), and thus, if suspected, sera have to be tested against different 
related viruses and results have to be subsequently confirmed by different assays. The 
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diagnosis methods can be subdivided into two main groups: the first includes the enzyme-
linked immunosorbent assays (ELISAs) and immunoflourescence (IF) based tests; the 
second includes the Plaque Reduction Neutralization Test (PRNT), considered as the gold-
standard (Dauphin G. Zientara S., 2007) which an be carried out using a highly sensitive 
50% or less-sensitive 90% endpoint (PRNT50, and PRNT90 respectively), both of which 
require the constant availability of standardised-validated infectious viruses and appropriate 
cell cultures (Sambri V., et al., 2013). The hemagglutination-inhibition test (HIA) is still 
used to detect pan-flavivirus immune response whereas the complement fixation test (CFT) 
is rarely used in today’s laboratories. Thus, initially serological testing was based on the 
techniques included in the first group are widely used due to their relative applicability in 
routine laboratory and the ability to automate a part of the workflow (IgM antibody capture 
assays (MAC-ELISA) and in indirect IgG ELISAs), but they are less specific as a 
consequence of their inability to distinguish between WNV-specific and cross-reactive 
antibody responses (Dauphin G., Zientara S., 2007) and any positive result identified, using 
these methods, must be confirmed by the more specific tests, i.e., those that constitute the 
second group. The PRNT50 method is considered the gold-standard for detecting immune 
responses which is able to detect, specifically, low titre, low avidity immune responses 
(Sambri V., et al., 2013).  
3.11 VACCINES 
Even though notable progress for WNV vaccine development has been made, no FDA 
approved vaccines exist for human use (Dauphin G. and Zientara S., 2007; Rossi SL., et al., 
2010; Beasley DW., 2011), and their cost-effectiveness for human treatment is still 
uncertain. On the other hand, there are effective, licensed vaccines for the treatment of 
horses that had greatly contributed to the decrease incidence of equine cases in the US, 
whilst the number of human cases still remains growing (Ward MP., et al., 2006; Dauphin 
G. and Zientara S., 2007). There are several strategies being pursued for WNV vaccine 
development (Table 5). The first strategy is based on the use of live attenuated or chemically 
inactivated virus obtained from infected cell cultures or from inoculated suckling mouse 
brains (Ng T., et al., 2003; Samina I., et al., 2005). Fort Dodge Animal Health developed 
this strategy by formalin inactivating whole virus (Innovator®, FortDodge, Princeton, NJ, 
US) and this formulation has been approved for horses (Rossi SL., et al., 2010). 
Additionally, a commercially available formaldehyde inactivated vaccine derived from 
infected suckling mice brains and live attenuated vaccines have been administered to 
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domestic geese in Israel (Malkinson M., et al., 2001; Samina I., et al., 2005). The second 
strategy involves the production of WNV antigens from a heterologous virus backbone. The 
vectors being used are: recombinant live canarypox vaccine that express prM and E genes 
formulated with Carbopol adjuvant (RecombitekTM), Yellow fever virus (ChimerivaxTM), 
and Dengue 4 (WNV-DENV4) (Pletnev AG., et al., 2003; Arroyo J., et al., 2004; Minke 
JM., et al., 2004; Monath TP., et al., 2006). The RecombitekTM (MerialLtd., Athens, GA, 
US) vaccine has been licensed for use in horses. The third approach is through use of 
recombinant DNA technology that has been applied for engineering DNA and recombinant 
vaccines based on the use of viral proteins (or fragments of them) synthesized in diverse 
systems (from bacteria to insect cells and larvae) (Dauphin G. and Zientara S., 2007; Rossi 
SL., et al., 2010; Beasley DW., 2011). Vertical transfer of acquired maternal immunity to the 
offspring has been demonstrated in mice immunized with recombinant proteins (Alonso-
Padilla J., et al., 2011). For horses a plasmid DNA vaccine, pCBWN, that encodes WNV 
structural antigens (prM-E) (Fort Dodge and Center for Disease Control and Prevention) 
commercialized in the US. The success of veterinary vaccines has encouraged others to 
develop these and other strategies for human vaccines that should induce a good response on 
higher risk groups and achieve an affordable cost/benefit ratio (Rossi SL., et al., 2010; 
Martin-Acebes MA., et al., 2012). 
 
 
 
 
 
 
 
 
Table 5. WNV vaccines. Partial list of licensed and preclinical vaccines against WNV 
(Rossi SL., et al., 2010). 
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4. INNATE IMMUNITY 
 
4.1 INNATE IMMUNITY TO VIRUS INFECTION 
The innate immune system acts as the first line of defense against invading viral pathogens 
and it is critically important for controlling infection. It consists of multiple antiviral 
programs that work in concert to control viral replication and spread as well as promoting 
the cell-mediated innate and adaptive immune responses. The proper and controlled 
induction of this aim of the immune response is mediated by specialized cellular proteins 
termed pattern-recognition receptors (PRRs). These are proteins expressed by a variety of 
cells, which are responsible for sensing the presence of pathogens invasion through 
evolutionary conserved viral components, known as pathogen-associated molecular patterns 
(PAMPs), such as glycoprotein, double-stranded RNA (dsRNA), single-stranded RNA 
(ssRNA), and DNA that are broadly shared by different microorganisms and essential to the 
survival or infectivity of the pathogen (Takeuchi O. and Akira S., 2009; Rossi SL., et al., 
2010; Jensen S., et al., 2012; Ye J., et al., 2012; Fredericksen BL., 2014). Currently, three 
classes of PPRs have been shown to be involved in the recognition of PAMPs in non-
immune cells or cells of the innate immune system, namely: retinoic acid-inducible gene I 
(RIG-I)-like receptors (RLRs); Toll-like receptors (TLRs); and nucleotide oligomerization 
domain (NOD)-like receptors (NLRs). Among these receptors types, RLRs and TLRs detect 
pathogen structures in immune cells and active intracellular signalling cascades that leads to 
production of type I interferons (IFNs) and proinflammatory cytokines whereas NLRs are 
known to play a role in the production of mature interleukin-1-beta through activation of 
caspase-1 (Fig. 15) (Kanneganti TD., et al., 2007; Petrilli V., et al., 2007).  
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Figure 15. Cell-intrinsic innate antiviral response. Schematic of the key signalling 
pathways contributing to the innate antiviral response to WNV. Abbreviations: retinoic acid-
inducible (RIG-I)-like receptors (RLRs); Toll-like receptor (TLRs); melanoma 
differentiation antigen 5 (MDA5); laboratory of genetics and physiology 2 (LGP2); 
nucleotidebinding oligomerization domain (NOD)-like receptors (NLRs); NLR family PYD-
containing 3 (NLPR3); TIR-domain-containing adapterinducing interferon-β (TRIF); 
myeloid differentiation primary response 88 (MyD88); interferon stimulated genes (ISGs) 
(Fredericksen BL., 2014). 
 
 
4.1.1 RIG-I-LIKE RECEPTORS SIGNALLING  
The RIG-I-like receptors (RLRs) are cytosolic proteins consisting of three members of 
relevance: RIG-I (also known as DDX58), melanoma differentiation-associated antigen 5 
(MDA5), and laboratory of genetics and physiology-2 (LGP2) (Kang DC., et al., 2002; 
Yoneyama M. et al., 2004; Yoneyama M., et al., 2005; Yoneyama M. and Fujita T., 2007; 
Jensen S. and Thomsen R., 2012). RLRs are critical sensors of viral RNAs in the cytoplasm 
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and are expressed basally in most cells of human organism, except plasmacytoid dendritic 
cells (pDCs) which preferentially employ TLRs for detection of RNA virus infection, and 
are induced to high levels by type I interferons (IFNs) (Kang DC., et al., 2004; Yoneyama 
M., et al., 2004; Kato H., et al., 2005; Yoneyama M., et al., 2005). However, in response to 
viruses that circumvent the endosomal TLRs of the pDCs by direct membrane fusion, 
cytosolic recognition by RLRs is assumed to be of great importance also in pDCs. RIG-I and 
MDA5 consist of two N-terminal tandem caspase-activation and recruitment domains 
(CARDs), an RNA helicase domain, and a C-terminal repressor domain (RD). In contrast, 
LGP2 lacks the tandem N-terminal CARDs but contains an RNA helicase domain and a C-
terminal repressor domain. Whereas the helicase domain and RD are important for the 
recognition of viral RNA, the CARDs are essential for triggering intracellular signalling 
cascades (Yoneyama M., et al., 2004; Saito T., et al., 2007). LGP2, that lacks the N-terminal 
CARD, has been suggested to function as a negative regulator, rather than an initiator, of 
RLR signalling (Komuro A. and Horvath CM., 2006; Venkataraman T., et al., 2007; Suthar 
MS., et al., 2012). RNA virus infection leads to the generation of dsRNA and RNAs with 5’-
triphosphate ands in infected cells. Long dsRNA is not normally present in cells, and 5’ ends 
of host RNAs are typically capped. In response to detection of viral RNAs in the cytoplasm, 
both RIG-I and MDA5 are post-translationally modified and translocate to mitochondria and 
mitochondrial-associated membranes (Gack MU., et al., 2010; Horner SM., et al., 2011; Liu 
HM., et al., 2012; Wies E., et al., 2013). Here, RIG-I and MDA5 interact with an adapter 
protein designated IFN-β promoter stimulator-1 (IPS-1), also know as mitochondrial 
antiviral signalling (MAVS), through CARD repeats that leads to the formation of the IPS-
1/MAVS-signalosome, comprised of RLR signalling adaptors, protein kinases, and 
transcription factors (interferon regulatory factors (IRF)-1, -3, -5, -7, and NF-κB) (Daffis S., 
et al., 2007; Daffis S., et al., 2008; Daffis S., et al., 2009; Lazear HM., et al., 2013). IPS-1-
deficient mice are impaired in the production of proinflammatory cytokines and type I in 
response to all RNA viruses recognized by RIG-I and MDA5 (Kumar H., et al., 2006; Sun 
Q., et al., 2006). These findings indicate that IPS-1plays essential roles in RIG-I/MDA5 
signalling (Takeuchi and Akira., 2009). IPS-1 itself is probably not directly involved in the 
signalling process, but serves as a platform to coordinate the activation of two of the 
signalling pathway also utilized by the TLRs (Jensen S. and Thomsen R., 2012). Recently, 
another adaptor, stimulator of IFN genes (STING, also called MITA) was described 
(Ishikawa H. and Barber GN., 2008; Zhong B., et al., 2008). STING is also found in the 
mitochondrial membrane but resides predominantly in the endoplasmic reticulum. 
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Considering that STING interacts with RIG-I and IPS-1 in the mitochondrial membrane, this 
potentially opens the possibility for cross talk between the two organelles in viral sensing 
(Arnoult D., et al., 2009). However, the precise importance of such interactions is not clear 
at this moment (Jensen S. and Thomsen R., 2012). IPS-1 coordinates the activation, through 
TNF receptor-associated death domain (TRADD), of two of the same pathways as those 
activated by TRIF during downstream signalling from TLR3: the activation of RIP1 for NF-
kB nuclear translocation, and the activation of IKKs, for IRF3 phosphorylation and 
translocation (Hemmi H., et al., 2004). Activated transcription factors translocate to the 
nucleus and drive transcription of IFN-β, IFN-α4, proinflammatory cytokines, and 
interferon-stimulated genes (ISGs) that aid in cellular defense against viral infection (Quicke 
KM. and Suthar MS., 2013). In addition, research also suggests that RIG-I activation can 
trigger inflammasome formation and cysteine-aspartic protease 1 (caspase-1) activity, 
leading to the maturation of proinflammatory cytokines such as interleukin-1β (IL-1β) 
(Poeck H., et al., 2010). This IPS-1-indipendent pathway is also used by NLRP3 (Jensen S. 
and Thomsen R., 2012). 
4.1.2 TOLL-LIKE RECEPTORS SIGNALLING  
In addition to RLRs, TLRs are important for recognizing virus infection. TLRs are 
transmembrane glycoprotein receptors with an N-terminal extracellular PAMP-binding 
region, a transmembrane domain (LRRs) and a C-terminal cytoplasmic domain designed the 
Toll/IL-1 receptor (IL-1R) homology (TIR) domain (Akira S., et al., 2006) which mediates 
downstream signalling events upon activation of the receptor (Bowie A. and O’Neill LAJ., 
2000; Akira S. and Takeda K., 2004). TLRs, unlike the RLRs, are transmembrane proteins 
suitable for detecting distinct viral and bacterial PAMPs outside of the cells as well as in 
cytoplasmic vacuoles after phagocytosis or endocytosis (Takeuchi O. and Akira S., 2009). 
Upon extracellular ligand recognition, TLR dimerization is thought to be induced, bringing 
together the cytoplasmic TIR domains and subsequently recruting adaptor molecules to 
initiate the signalling process (Akira S., et al., 2006; O’Neill LAJ., 2006). Among more than 
10 TLRs present in mammals, TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9 are thought to 
be importance in the recognition of structural components of RNA viruses. Among these 
receptors, TLR2 and TLR4, present on the plasma membrane, are involved in the 
recognition of viral envelope proteins on the cell surface. By contrast, the TLRs 3, 7, 8 and 
9, reside on cytoplasmic vesicles, such as endosomes and ER, and recognize microbial 
nucleotides (Takeuchi O. and Akira S., 2009; Quicke KM. and Suthar MS., 2013). TLR3 
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recognizes dsRNA, whereas TLR7/8 and TLR9 recognize GU-rich ssRNAs and DNA with 
CpG motifs, respectively (Alexopoulou L., et al., 2001; Diebold SS., et al., 2004; Heil F., et 
al., 2004). TLR3 and TLR7/8 are important in regulating immunity to WNV but, unlike the 
RLRs, function in a cell- and tissue-specific manner: while TLR3 signalling in cortical 
neurons, but not in macrophages or DCs, promotes type I IFN production and is required for 
controlling virus replication (Daffis S., et al., 2008a); TLR7/8 signalling is important for 
triggering type I IFN and proinflammatory cytokine production within neurons, 
macrophages, and keratinocytes, but not DCs (Welte T., et al., 2009; Szretter KJ., et al., 
2010). Upon binding PAMP RNA, all TLRs, except TLR3, activate three major signalling 
pathways: mitogen-actived protein kinases (MAPKs), one or more interferon regulatory 
factors (IRFs), and a nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), 
that lead to the production of type I IFN and proinflammatory cytokines via myeloid 
differentiation factor 88 (MyD88) (Adachi O., et al., 1998; Yamamoto M., et al., 2003). 
MyD88 is a protein comprised of a C-terminal TLR-binding TIR domain and an N-terminal 
death domain (DD), and through the latter it forms a complex with two interleukin-1 
receptor-associated kinases (IRAKs). Mammals have four IRAK family members, called 
IRAK-1, IRAK-2, IRAK-M and IRAK-4 that are characterized by an N-terminal DD and a 
C-terminal serine/threonine kinase domain. Upon activation, IRAK-4 phosphorylates IRAK-
1 that, activated, binds the C-terminal domain of TNF receptor-associated factor 6 (TRAF6). 
This IRAK-1/ TRAF6 complex then dissociates from the TLR. Downstream of IRAKs, 
TRAF6 is activated and catalyzes the formation of a K63-linked polyubiquitin chain on 
IKK-γ/NF-kB essential modulator (NEMO) (Chen ZJ., 2005) and on tumor growth factor-β 
(TGF-β)-activated kinase 1 (TAK1). IKKγ subsequently associates with IKKα and IKKβ. 
IKKβ is phosphorylated by the activated TAK1 associated with the TAK1 binding protein 1 
(TAB1), TAB2, and TAB3. This leads to the IKK-mediated phosphorylation and subsequent 
degradation of IkB, which in the unphosphorylated state is coupled to NF-kB. NF-kB, 
formerly sequestered in the cytosol, is now free to enter the nucleus to induce gene 
expression. TAK1 in association with TAB1, TAB2, and TAB3 also triggers a MAPK 
pathway leading to the formation of AP-1. Similar to NF-kB, AP-1 enters the nucleus, and 
together, NF-kB and AP-1 induce the expression of genes involved in inflammatory 
responses (Akira S. and Takeda K., 2004; Takeuchi O. and Akira S., 2009). IRF5 and IRF7 
also interact with the complex of IRAKs and TRAF6. This leads to IRAK1-dependent 
phosphorylation and subsequent nuclear translocation of both molecules (Takaoka A., et al., 
2005; Uematsu S., et al., 2005). While IRF5 is involved primarily in regulating the induction 
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of proinflammatory cytokines (e.g., IL-6 and IL-12p40) (Takaoka A., et al., 2005), IRF7 is a 
key mediator in TLR7/TLR8-dependent type I IFN production (Honda K., et al., 2005; 
Honda K., et al., 2006). 
TLR3 is localized to the intracellular compartment in macrophages, B lymphocytes, and 
cDCs and is found both intracellulary and on the surface of NK cells, epithelial cells and 
fibroblasts (Hornung V., et al., 2002; Matsumoto M., et al., 2003; Kawai T. and Akira S., 
2008; Paludan SR., et al., 2011). In response to stimulation with dsRNA, TLR3 dimerizes 
and recruits another adapter protein, shared only with TLR4 among TLRs: TIR domain-
containing adapter inducing IFN-β (TRIF) (Yamamoto M., et al., 2002; Oshiumi H., et al., 
2003; Yamamoto M., et al., 2003). TRIF associates with TRAF6 through TRAF-binding 
motifs presents in its N-terminal portion for the activation and translocation of NF-kB and 
AP-1 as that seen for TLRs signalling described above. In addition to this pathway, recent 
studies showed that TAK-1-indipendent pathway of NF-kB activation is also triggered. This 
pathway is initiated when TRIF interacts with RIP1 and RIP3 via the RHIM (receptor-
interacting (RIP) homotypic interaction motif) presents in its C-terminal portion (Sato S., et 
al., 2003; Meylan E., et al., 2004) and subsequently converges on IKKβ, which is also used 
by the TAK1-dependent route (Meylan E., et al., 2004). TRIF associates also with TRAF3 
for association with TRAF family member-associated NF-kB activator (TANK)-binding 
kinase 1 (TBK1) and IKKε. TBK1/IKKε subsequently phosphorylates IRF3 (Sharma S., et 
al., 2003; Fitzgerald KA., 2003). The downstream signalling molecules for the expression of 
IFN-inducible genes are shared between the TLR3 and RLR signalling pathways. IRF3, 
upon phosphorylation, dimerizes and translocates to the nucleus to initiate transcription of 
type I IFNs (IFN-β and IFN-α4). In a positive feedback system, these type I IFNs, among 
many other effects, upregulate the level of IRF7 expression in responding cells. IRF7, when 
upregulated, is phosphorylated by TBK1/IKKε, as is IRF3. Dimerized IRF7 then stimulates 
further type I IFN release (entire range of IFN-α species) (Kawai T. and Akira S., 2006). 
Furthermore, as type I IFN release stimulates the expression of TLR3 in cells that were 
initially TLR3 negative, this adds to the positive feedback loop, enhancing the capacity to 
provide the antiviral response. In addition to the TLR3-mediated expression of type I IFNs 
and inflammatory cytokines, TLR3 activation also provides a link between the innate 
immune system and the adaptive immune system (Jensen S. and Thomsen R., 2012). 
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4.1.3 NOD-LIKE RECEPTORS SIGNALLING  
Nucleotide-binding oligomerization domain-containing (NOD)-like receptors (NLR), are 
cytosolic proteins regulating inflammatory and apoptotic responses, and recent studies point 
to the importance of these receptors in the antiviral defense (Jensen S. and Thomsen R., 
2012). These proteins contain: an LRR domain at the C-terminal, that is considered to be the 
sensor region of the NLRs; a NACHT (NAIP, CIITA, HET-E, TP-1) domain located 
centrally that mediates oligomerization and activation; and at the N-terminal an effector-
binding domain, most often a CARD or a pyrin domain (PYD), that signals downstream 
following induced proximity upon activation and oligomerization of the NLRs (Jensen S. 
and Thomsen R., 2012). NLRP3 (NOD-, LRR-, and pyrin domain-containing 3) 
oligomerizes upon activation and recruits an adapter, ASC (apoptosis-associated speck-like 
protein containing a CARD), and procaspase-1 to form an inflammasome complex. The 
inflammasome is an innate immune signalling complex comprised of cytosolic PRRs (34 
NLR genes in mice and 22 NLR genes in humans) that regulates immune programmes and 
promotes viral clearance through the secretion of pro-inflammatory cytokines of the IL-1β 
family, including IL-1β, IL-18, and IL-33. Inflammasome activation is regulated by two 
signals: 1. A priming signal to induce the secretion of pro-inflammatory cytokines of the IL-
1β family, including IL-1β, IL-18, and IL-33 which can be mediated by the TLR, RLR, or 
NLR signalling pathways; and 2. A maturation signal wherein the inflammasome complex, 
comprised of an activated NLR, ASC adaptor protein and caspase-1, that processes pro-IL-
1β and pro-IL-18 into their mature forms which are subsequently secreted from the cell. 
These cytokines can have opposing effects: can elicit protective immunity by promoting 
immune cell trafficking to and activation at sites of infection, and can trigger pathological 
responses by driving a programmed cell death response known as pyropoptosis (Suthar MS., 
et al., 2013; Quicke KM. and Suthar MS., 2013). 
 
4.1.4 TYPE I INTERFERON SIGNALLING  
RLR and TLR signalling both activate IRF transcription factors, in particular IRF3 and 
IRF7, which are essential for regulating the type I IFN response following viral infections 
(Sato M., et al., 2000; Honda K., et al., 2005). These IRFs induce the production of type I 
IFNs (IFN-α and IFN-β) that, together with type II (IFN-γ) and type III (IFN-λ) IFNs, act as 
important innate immune system controls of viral infections (Samuel MA and Diamond MS., 
2006). IFN-α and IFN-β is produced by most cell types following virus infection and 
induces an antiviral state by upregulating genes with direct and indirect antiviral functions. 
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IFN α/β are secreted from the cell and can bind to the IFN-α and IFN-β receptor complex 
(IFNAR) in an autocrine or paracrine manner, leading to activation of the receptor-
associated kinases tyrosine kinase 2 (TYK2) and JAK1. These events are followed by 
phosphorylation of STAT1 (signal transducer and activator of trascription 1), STAT2 and 
assembly of the ISG factor 3 (ISGF3) complex, consisting of a STAT1– STAT2 heterodimer 
and IRF9 (Quicke KM. and Suthar MS., 2013). This complex translocates to the nucleus and 
binds specific DNA sequences known as interferon stimulated response elements (ISRE) to 
initiate transcription of IFN-stimulated genes (ISGs) (Horvath CM., 2004). In addition, 
inhibitor of NF-κB kinase‑ε (IKKε) phosphorylates STAT1 at serine 708 to alter the 
specificity of the ISGF3 complex, thus enhancing the expression of IKKε-dependent 
antiviral genes, including IFN-induced protein with tetratricopeptide repeats 2 (IFIT2) and 
ADAR1 (also known as DRADA) (Tenoever BR., et al., 2007; Perwitasari O., et al., 2011). 
 
4.2 INNATE IMMUNE EVASION STRATEGIES OF WNV 
In order to replicate and spread, WNV has evolved mechanisms to counteract the innate 
immune pathways of the host cells (Katze MG., et al., 2002) (Fig. 16). With respect to RLR 
signalling, initial observations evaluating the kinetics of IRF3 activation following WNV 
infection revealed a disparity between early viral protein accumulation and IRF3 activation, 
suggesting that WNV either actively antagonizes or evades detection by RLRs. Subsequent 
studies indicated that WNV uses a passive evasion strategy, possibly by masking or 
sequestering viral RNA from recognition by RLRs (Fredericksen BL., et al., 2004). In 
support of this finding, WNV replication complexes, which are a source of viral dsRNA, 
accumulate in ER membrane vesicles (Gillespie LK., et al., 2010), thus providing a possible 
mechanism for WNV to avoid sensing by RLRs. The exact mechanism by which WNV 
evades PRR detection is not understood yet. Recent studies revealed that WNV does not 
actively inhibit the RIG-I pathway leading to the production of IFN α/β. Rather, WNV 
strains appear to delay activation of PRR signalling long enough to give the virus a 
replicative advantage within the cells during the early stages of infection (Fredericksen BL., 
et al., 2006). Virus replication during this window period supports an accumulation of viral 
proteins that exert effects on IFN α/β actions (Keller BC., et al., 2007). This evasion strategy 
allows WNV to establish infection and synthesize viral factors that subsequently block other 
downstream innate immune signalling pathways, namely TLR3 and type I IFN signalling 
(Keller BC., et al., 2006; Wilson JR., et al., 2008).  
WNV has also been shown to interfere with the type I IFN response. Several groups have 
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recently reported that Lineage 1 WNV strains, but not lineage 2 WNV-MAD (strain 
Madagascar-AgMg798), is capable of blocking the phosphorylation of TYK2 to inhibit type 
I IFN-induced phosphorylation and activation of STAT1 and STAT2. This inhibition 
correlates with the onset of viral protein synthesis within infected cells. The exact viral 
protein that inhibits TYK2 has not yet been identified, but it has been proposed that the 
NS2A, NS2B3, NS4A and NS4B viral proteins each have inhibitory activity against IFN 
signalling (Keller BC., et al., 2007). In support of this study, the WNV non-structural 
proteins mediate the degradation of IFNAR1 through both lysosome- and proteasome-
dependent pathways (Evans JD., et al., 2011). It is unclear whether the inhibition of TYK2 
and the degradation of IFNAR1 are two separate events or are directly linked, and this 
warrants further investigation into the mechanism involving inhibition of type I IFN 
signalling by WNV. Other strategies by which WNV evades IFN signalling include 
redistribution of cellular cholesterol to sites of viral replication complexes, thus altering 
membrane-associated signalling in favour of viral replication (Mackenzie JM., et al., 2007), 
and synthesis of the viral non-coding subgenomic RNA, which has been identified as an IFN 
antagonist (Schuessler A., et al., 2012). The viral proteins that are responsible for inhibiting 
these IFN signalling components have not been identified. However, several WNV proteins 
have been implicated in the antagonism of the type I IFN signalling cascade. Both structural 
and non-structural proteins of lineage 1 WNV suppress type I IFN signalling (Evans JD., 
2007; Suthar MS., et al., 2012a): NS2A (Liu WJ., et al., 2005; Liu WJ., et al., 2006), NS2B 
(Liu WJ., et al., 2005), NS3 (Liu WJ., et al., 2005), NS4A (Liu WJ., et al., 2005), NS4B 
(Liu WJ., et al., 2005; Munoz-Jordan JL., et al., 2005; Evans JD., 2007) and NS5 (Laurent-
Rolle M., et al., 2010) all suppress type I IFN production and/or signalling, albeit through 
varied mechanisms.  
WNV actively evades the antiviral effects of IFIT1, an ISG protein that is highly induced 
following viral infection. IFIT1 exerts its antiviral function through multiple mechanisms, 
including interacting with eukaryotic translation initiation factor 3 (eIF3) to inhibit trans-
lation, inhibiting translation of viral RNAs lacking 2′-O-methylation, sequestering viral 
RNAs that contain a 5′ triphosphate and directly interacting with viral proteins to inhibit 
their function (Fensterl V. and Sen GC., 2011). A WNV mutant lacking 
2′-O-methyltransferase activity (WNV-NS5-E218A) is inhibited in cells expressing IFIT 
genes, revealing that WNV uses 2′-O-methylation as a mechanism to evade the antiviral 
effects of IFIT1; indeed, wild-type WNV strains show no growth advantage in Ifit1−/− cells 
or mice compared with in wild-type cells or mice (Szretter KJ., et al., 2012). 
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Figure 16. Cell-intrinsic innate immune response to West Nile virus infection. Innate 
immune responses to, and immune evasion by, West Nile virus (WNV). a | The recognition and 
binding of non-self RNA ligands by the RIG-I-like receptors (RLRs) retinoic acid-inducible gene I protein (RIG‑I), 
melanoma differentiation antigen 5 (MDA5) and LGP2 induces the activation of these receptors through ATP hydrolysis, 
followed by a conformational change in the RLR, oligomerization of the RLR and the subsequent RLR subcellular 
redistribution to membranes. Following this redistribution, RIG‑I and MDA5 bind to the adaptor protein MAVS 
(mitochondrial antiviral signalling). Formation of the MAVS signalling synapse drives activation and nuclear translocation 
of the latent transcription factors IFN regulatory factor 3 (IRF3) and nuclear factor-κB (NF‑κB), which induce expression of 
their target genes, including interferon β (IFNβ). WNV is thought to use a passive evasion strategy, possibly by masking or 
sequestering viral RNA (not shown). WNV proteins might also inhibit type I IFN production. b | Following binding of non-
self RNA ligands within the endosomal compartment, Toll-like receptor 3 (TLR3), TLR7 and TLR8 signal through their 
adaptor proteins — TRIF (TIR domain-containing adaptor inducing IFNβ) and MYD88 (myeloid differentiation 88) — to 
promote NF‑κB-, IRF3- and IRF7‑dependent gene expression. WNV inhibits TLR3 signalling. WNV proteins might also 
inhibit type I IFN production. c | IFNβ is secreted from the infected cell and binds in an autocrine and paracrine manner to 
IFNα and IFNβ receptor complex 1 (IFNAR1), leading to phosphorylation of the associated tyrosine kinase 2 (TYK2) and 
Janus kinase 1 (JAK1) and assembly of the trimeric IFN-stimulated gene factor 3 (ISGF3) complex containing signal 
transducer and activator of transcription 1 (STAT1)–STAT2 heterodimers and IRF9. This complex translocates to the 
nucleus and amplifies cell-intrinsic immunity by promoting the expression of IFN-stimulated genes (ISGs) and various 
IFNα subtypes. The IFN-induced phosphorylation of STAT1 by inhibitor of NF-κB kinase (IKKε) further enhances 
expression of a subset of ISGs. WNV blocks the activity of TYK2 and induces the degradation of IFNAR1. d | The NLRP3 
(NOD-, LRR- and pyrin domain-containing 3) inflammasome is activated in response to WNV infection, resulting in 
cleavage of pro‑interleukin‑1β (pro-IL‑1β) into the mature IL‑1β form. IL‑1β is secreted from the cell and binds to IL‑1 
receptor (IL‑1R) to trigger activation of NF‑κB and transcription of NF‑κB-dependent genes, as well as to regulate ISG 
expression (Suthar MS., et al., 2013). 
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AIM 
West Nile virus (WNV) is an emerging neurotropic, arthropod-borne flavivirus that is 
maintained in nature in an enzootic transmission cycle between mosquitoes and birds, 
although the virus also infects and causes disease in other vertebrates. Indeed, WNV can 
occasionally infect humans through mosquito bites, and human-to-human transmission via 
infected blood or organ donation has also reported. In 70%-80% of human cases, WNV 
infection remains asymptomatic. 20-40% of human cases may develop a mild flu-like 
illness, and less than 1% of clinical cases progress to severe neuroinvasive disease such as 
encephalitis, meningitis or acute flaccid paralysis, all of which may be fatal or accompanied 
by long term neurological sequelae.  
Based on nucleotide sequence data, WNV strains are phylogenetically classified into at least 
five genetic lineages, but only lineages 1 and 2, which have a nucleotide sequence identity of 
approximately 75%, have been associated with major epidemics. WNV strains belonging to 
lineage 1 distributed throughout the world and have been associated with outbreaks of 
encephalitis and meningitis in Africa, Europe, the Middle East, India, and North America. 
WNV strains belonging to lineage 2 were initially confined to the Africa subcontinent and 
the island countries of Madagascar and Cyprus and were considered to be less neurovirulent 
than lineage 1 strains up to their association to meningo-encephalitis outbreaks in Greece in 
2010. In Italy, the first human cases of WNV-associated fever and/or neurological disorders 
were reported in 2008 in Emilia Romagna and, since then, WNV circulation was thereafter 
reported in other Italian regions (Veneto, Lombardia), with occurence of several human 
cases.  On basis of phylogenetic analysis, the WNV strains that caused Italian outbreaks in 
2008-2009, belonged to lineage 1 strains. Although the WNV strains are highly genetically 
conserved, stochastic mutations in their genome may lead to the emergence of new strains, 
as was observed in Italy in 2011 with the identification of new lineage 1 strains that caused 
human cases of WNV neuroinvasive infections. Furthermore, the first human cases of WNV 
fever caused by a lineage 2 strain, related to Hungarian-Greek strains, were also reported in 
the Marche and Sardinia regions. 
A large variety of WNV strains from America have been described in terms of genetic, 
phenotypic and pathogenic properties, but there are few experimental studies on biological 
properties of WNV strains that are circulating in Europe/Italy and on WNV lineage 2 
pathogenic strains. 
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The aim of this study is investigate the growth kinetics of five strains of WNV: four WNV 
strains belonging to lineage 1, including one from North America and three isolated in Italy 
and one WNV strain belonging to lineage 2 from Italy. The phenotypic properties of these 
WNV strains were examined to observe if there were differences in replication in two cell 
types: Vero and human astrocytes cells. Moreover, in order to understand if IFN may 
influence the growth kinetics of divergent lineage 1 and 2 viruses, we compared the 
influence of IFN-α action on their capacity of replication in Vero and human astrocytes 
cells.  
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MATERIALS AND METHODS 
1. CELLS AND VIRUSES 
Vero and 1321N1 cell lines were maintained at 37°C in a humidified atmosphere containing 
5% CO2. Vero cells (African green monkey kidney epithelial cells) were grown in Minimal 
Essential Medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS), L-glutamine 
and penicilline-streptomycin (MEM complete). 1321N1 (human astrocytoma) cell line was 
propagated in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS), L-glutamine and penicilline-streptomycin (DMEM complete). 
Five strains of WNV were used for this study:  
• Four strains belong to lineage 1, clade 1a: WNV-NY99 (GeneBank accesion no. 
DQ211652), WNV-TOS (GeneBank accesion no. HM991273), WNV-AN 1 
(GeneBank accesion no. JN858069), and WNV-DON B; 
• One strain belongs to lineage 2: WNV-CIP.  
All virus strains were isolated from human plasma inoculated on Vero cells. Virus isolates 
were propagated for one passage on Vero or 1321N1 cells. Viral stocks were aliquoted and 
stored at -80C°.  
 
2. VIRUS TITRATIONS 
Viral titres were quantified as TCID50 endpoint titers (TCID50/mL) calculated by the method 
of Spearman-Karber. Briefly, the samples were titrated on 96-well flat-bottom tissue culture 
plate where Vero cells were seeded into all wells. Each sample was serially diluited in a 10-
fold series and it was titrated in triplicate. The 96-well titration plates were incubated at 
37°C in a humidified 5% CO2 incubator and presence of cytopathic effect was evaluated 
after 3-5 days. 
 
3. GROWTH CURVES 
For analysis of virus growth kinetics, 1 day after seeding 1 x 106 per well of Vero or 1321N1 
cells in a 6-well plates, cells were infected with WNV-NY99, WNV-TOS, WNV-AN 1, 
WNV-DON B or WNV-CIP at MOI of 1 and 0,01 in a volume of 4 ml of MEM or DMEM, 
respectively. Cells were infected for 1.5 hours, inoculum was removed and cells were 
washed two times with fresh medium and 4 ml of appropriate medium, MEM or DMEM, 
was added. At 2, 4, 6, 8, 10, 12, 18, 24, 48, 72 and 80 hours after infection, cell culture 
supernatants were harvested and stored at -80°C. The supernatants were titrated in 96-well 
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plates by TCID50 method on Vero cells as described above. Each growth curve experiment 
was performed in triplicate, and each TCID50 assay was undertaken in duplicate. 
 
4. VIRUS STRAINS SUSCEPTIBILITY TO INTERFERON-α  (IFN-α) 
ACTION 
24 hours after seeding 1 x 106 per well of Vero or 1321N1 cells in a 6-well plates, cells were 
incubated for 24 hours in presence (pre-treatment) and in absence of 100 U/ml of IFN-α-2b 
human (H6166-10UG SIGMA). After 24 hours, in presence and in absence of IFN-α-2b, 
Vero and 1321N1 cells were infected with WNV-NY99, WNV-TOS, WNV-AN 1, WNV-
DON B or WNV-CIP at MOI of 1 in a volume of 4 ml of MEM or DMEM. Cells were 
infected for 1.5 hours, inoculum was removed and cells were washed two times with fresh 
medium and 4 ml of appropriate medium, MEM or DMEM, with and without 100U/ml of 
IFN-α-2b was added. At 0, 24 and 48 hours post-infection, the cell culture supernatants were 
harvested and stored at -80°C. The supernatants were titrated in 96-well plates by TCID50 
method on Vero cells. Each experiment was performed in triplicate, and viral titre, at each 
time point, was evaluated in duplicate.  
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RESULTS 
In the present study, we compared the growth properties of five WNV strains in two cell 
lines: Vero (African green monkey kidney epithelial cells) and 1321N1 (human 
astrocytoma). Four WNV strains belong to lineage 1: WNV-NY99 from North America, 
WNV-TOS, WNV-AN 1 and WNV-DON B from Italy. One WNV strain isolated in Italy, 
WNV-CIP, belongs to lineage 2. In order to understand the influence of IFN-α on viral 
growth, we compared the influence of IFN-α on growth kinetics of different lineage 1 and 2 
WNV strains in Vero and 1321N1 cells. 
 
1. GROWTH PROPERTIES OF WNV STRAINS ON VERO CELLS 
To investigate possible differences on the kinetics of replication of both lineages 1 and 2 
WNV strains circulating in Italy, we compared growth kinetics of viruses on Vero cells. 
Cells were infected at a multiplicity of infection (MOI) of 1 and 0.01 with WNV-NY99, 
WNV-TOS, WNV-AN-1, WNV-DON B or WNV-CIP. At 2, 4, 6, 8, 10, 12, 18, 24, 48, 72 
and 80 hours after infection, the cell culture supernatants were harvested and titrated by 
TCID50 method on Vero cells. For each MOI and viral strain tested, growth curve 
experiments were performed in triplicate. Viral titre, at each time point, was evaluated in 
duplicate and the results are summarized in Fig. 17.  
Viral growth analyses in Vero cells revealed that all WNV strains examined display a similar 
growth kinetic. Extracellular infectious particles were detectable starting from 12 hours post-
infection for all WNV strains for each MOIs tested. At 18 hours post-infection the titre 
reached was approximately 106 TCID50/ml and 104 TCID50/ml for all WNV strains at MOI 
of 1 and 0.01, respectively. At 24 hours post-infection the titres were in the range 107-108 
TCID50/ml at MOI of 1 and 105-106 TCID50/ml at MOI of 0.01. When cells were infected at 
MOI of 1, at 48 hours post-infection the peak of infectious virus production was reached 
with a titre of approximately 1011 TCID50/ml for WNV-NY99, WNV-TOS and WNV-AN 1, 
and about 1010 TCID50/ml for WNV-DON B and WNV-CIP and at 72 and 80 hours post-
infection viral titres slowly decreased and the plateau was reached with titres ranging from 
1010-1011 TCID50/ml. When cells were infected at MOI of 0.01, the peak of infectious virus 
production was reached at 72 hours post-infection with a titre of about 109 TCID50/ml for all 
WNV strains tested and the plateau was reached at 80 hours post-infection with viral titles of 
109TCID50/ml, the same title reached at 72 hours post-infection.  
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Figure 17. Growth kinetics of WNV strains on Vero cells. Vero cells were seeded in six-
well dishes and infected with WNV-NY99, WNV-TOS, WNV-AN 1, WNV-DON B, or 
WNV-CIP at multiplicity of infection (MOI) of 1 (A) and 0.01 (B). At indicated times 2, 4, 
6, 8, 10, 12, 18, 24, 48, 72 and 80 hours post-infection, cell culture supernatants were 
harvested and the titres of the viruses were determined by TCID50/ml assay on Vero cells. 
Each growth curve experiment was performed in triplicate, and each TCID50 assay was 
undertaken in duplicate. Results are expressed as the mean TCID50/ml ± standard deviation. 
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2. GROWTH PROPERTIES OF WNV STRAINS ON 1321N1 CELLS 
Astrocytes are star-shaped and constitute the most abundant cell type found in the CNS. 
They have a number of important functions in the brain homeostasis, including maintenance 
of functional integrity in the BBB, regulation of neuronal blood flow, modulation of 
neuronal health and activity through the uptake of excess neurotransmitters and secretion of 
nutrients. Moreover, astrocytes can produce acute-phase proteins and some pro-
inflammatory cytokines and play a crucial role in controlling leukocyte influx. Here, we 
compared the ability of four WNV strains belonging to lineage 1 (WNV-NY99, WNV-TOS, 
WNV-AN 1 and WNV-DON B) and one WNV strain belonging to lineage 2 (WNV-CIP) to 
replicate in 1321N1 cells (human astrocytoma cell line).  
1321N1 cells were infected at a multiplicity of infection (MOI) of 1 and 0.01 with WNV-
NY99, WNV-TOS, WNV-AN-1, WNV-DON B or WNV-CIP. At 2, 4, 6, 8, 10, 12, 18, 24, 
48, 72 and 80 hours after infection, the cell culture supernatants were harvested and titrated 
by TCID50 method on Vero cells. For each MOI and viral strain tested, growth curve 
experiments were performed in triplicate. Viral titre, at each time point, was evaluated in 
duplicate and results are summarized in Fig. 18.  
Viral growth analyses in 1321N1 cells revealed that all WNV strains display a similar 
growth kinetic although the kinetic of replication of WNV-CIP, lineage 2 WNV strain, was 
slightly delayed at early times post-infection compared to those lineage 1 WNV strains. 
When cells were infected at MOI of 1, extracellular infectious particles were detectable 
starting from 12 hours post-infection for all WNV strains, but the titres were approximately 
106 TCID50/ml for lineage 1 WNV strains and 104 TCID50/ml for lineage 2 WNV strain. By 
comparison, at 12, 18 and 24 hours post-infection, growth kinetic of WNV-CIP was delayed 
and the titers were decreased of approximately 10-100 fold, compared to those of lineage 1 
WNV strains at the same time points. However, for all WNV strains tested, the peak of 
infectious virus production was reached at 48 hours post-infection and the titres were in the 
range 109-1010 TCID50/ml. Then at 72 and 80 hours post-infection the plateau was reached 
with titres ranging from 109-1010 TCID50/ml.  
When cells were infected at MOI of 0.01, extracellular infectious particles were detectable 
starting from 12 hours post-infection for WNV lineage 1 strains and from 18 hours post-
infection for WNV lineage 2 strain, WNV-CIP. In fact, at early times post-infection, growth 
kinetic of WNV-CIP was delayed and the titers were decreased of approximately 10-100 
fold, compared to those of lineage 1 WNV strains. However, for all WNV strains tested, at 
48 hours post-infection the titre reached was approximately 107 TCID50/ml and the peak of 
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infectious virus production was reached at 72 hours post-infection with ranging from 108-109 
TCID50/ml. Then at 80 hours post-infection the plateau was reached, the viral titres slowly 
decrease with titres ranging from 107-109 TCID50/ml. 
Despite the slight growth delay of WNV-CIP at early times post-infection, 1321N1 cells 
were highly permissive for all WNV strains examined. 
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Figure 18. Growth kinetics of WNV strains on 1321N1 cells. 1321N1 cells were seeded in 
six-well dishes and infected with WNV-NY99, WNV-TOS, WNV-AN 1, WNV-DON B, or 
WNV-CIP at multiplicity of infection (MOI) of 1 (A) and 0.01 (B). At indicated times 2, 4, 
6, 8, 10, 12, 18, 24, 48, 72 and 80 hours post-infection, cell culture supernatants were 
harvested and the titres of the viruses were determined by TCID50/ml assay on Vero cells. 
Each growth curve experiment was performed in triplicate, and each TCID50 assay was 
undertaken in duplicate. Results are expressed as the mean TCID50/ml ± standard deviation. 
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3. WNV STRAINS SUSCEPTIBILITY TO INTERFERON-α  (IFN-α) 
ACTION ON VERO CELLS 
After comparing growth properties of WNV strains on Vero cells, we evaluated if different 
strains belonging to lineage 1 and 2 exhibited differential susceptibility to the antiviral 
effects of interferon-α (IFN-α). Vero cells were left treated or untreated with 100 U/mL of 
IFN-α for 24 hours to induce an intracellular antiviral state (IFN-pre-treatment) before 
infection. Then cells were infected at a multiplicity of infection (MOI) of 1 with WNV-
NY99, WNV-TOS, WNV-AN-1, WNV-DON B or WNV-CIP in the presence or absence of 
IFN-α and maintained under these conditions for the duration of the experiment. At 0, 24 
and 48 hours after infection, the supernatants were harvested and titrated by TCID50 method 
on Vero cells. For each viral strain tested, growth curve experiments were performed in 
triplicate, and viral titre at each time point was evaluated in duplicate. The results are 
summarized in Fig. 19.  
Viral growth analyses in Vero cells treated or untreated with 100 U/mL of IFN-α revealed 
that all WNV strains have similar susceptibility to IFN-α action. When cells were infected at 
MOI of 1 in absence of IFN-α, the titres for all WNV strains tested were in the range 107-108 
TCID50/ml and 109-1010 TCID50/ml at 24 and 48 hours post-infection, respectively. When 
cells were infected at MOI of 1, in presence of 100 U/ml of IFN-α, at 24 and 48 hours post-
infection the tires were in the range 104-105 TCID50/ml and 105-106 TCID50/ml, respectively. 
Thus, treatment with 100 U/ml of IFN-α2b greatly reduced approximately of 1.000-fold and 
10.000-fold infectious particle production in all WNV strains examined at 24 and 48 hours 
post-infection, respectively. These results demonstrate that all WNV strains tested are highly 
susceptible to antiviral process induced by IFN-α action and there are no differences in 
susceptibility among different WNV strains. 
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Figure 19. Growth kinetics of WNV strains on Vero cells and susceptibility to IFN-α  
action. Vero cells were pre-treated with 0 (bleu lines) or 100 U/mL IFN-α (red lines) for 
24h prior to WNV infection. Cells were then infected (1 MOI) with WNV-NY99, WNV-
TOS, WNV-AN 1, WNV-DON B, or WNV-CIP for 1,5 hours. Following infection, medium 
containing 0 (blue lines) or 100 U/mL IFN-α (red lines) was added to cells. At indicated 
times post-infection, cell culture supernatants were harvested and the titres of the viruses 
were determined by TCID50/ml assay on Vero cells. Each growth curve experiment was 
performed in triplicate, and each TCID50 assay was undertaken in duplicate. Results are 
expressed as the mean TCID50/ml ± standard deviation. 
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4. WNV STRAINS SUSCEPTIBILITY TO INTERFERON-α  (IFN-α) 
ACTION ON 1321N1 CELLS 
After comparing growth properties of WNV strains on 1321N1 cells and their susceptibility 
to interferon-α action on Vero cells, we evaluated if different strains belonging to lineage 1 
and 2 WNV exhibited differential susceptibility to the antiviral effects of interferon-α (IFN-
α) on 1321N1 cells. Cells were treated or untreated with 100 U/mL of IFN-α for 24 hours to 
induce an intracellular antiviral state (IFN-pre-treatment) before infection and then were 
infected at a multiplicity of infection (MOI) of 1 with WNV-NY99, WNV-TOS, WNV-AN-
1, WNV-DON B or WNV-CIP in the presence or absence of IFN-α. At 0, 24 and 48 hours 
after infection, the supernatants were harvested and titrated by TCID50 method on Vero cells. 
For each viral strain tested, growth curve experiments were performed in triplicate, and viral 
titre at each time point was evaluated in duplicate. The results are summarized in Fig. 20.  
Viral growth analyses in 1321N1 cells treated or untreated with 100 U/mL of IFN-α 
revealed that: when cells were infected at MOI of 1 in absence of IFN-α, the growth kinetics 
were similar for all WNV strains tested, with a slight delay in infectious particle production 
at 24 hours post-infection for WNV-CIP compared to that WNV lineage 1 strains and the 
titres for all WNV strains tested were in the range 106-108 TCID50/ml and 109-1010 
TCID50/ml at 24 and 48 hours post-infection, respectively. When cells were infected at MOI 
of 1, in presence of 100 U/ml of IFN-α, at 24 hours post-infection the tires for WNV-NY99, 
WNV-TOS and WNV-AN-1 were in the range 101-102 TCID50/ml and for WNV-DON B 
and WNV-CIP were in the range 103-104 TCID50/ml. At 48 hours post-infection the titres 
reached were approximately of 101 TCID50/ml for WNV-NY99, WNV-TOS and WNV-AN-
1, and in the range 103-104 TCID50/ml for WNV-DON B and WNV-CIP. Thus, treatment 
with 100 U/ml of IFN-α resulting in an approximate 6-log and 8-log decrease in infectious 
particle production in WNV-NY99, WNV-TOS and WNV-AN 1 at 24 and 48 hours post-
infection, respectively. For WNV-DON B and WNV-CIP titres were reduced of 
approximately 4-log and 6-log at 24 and 48 hours post-infection, respectively. These results 
demonstrate that, although WNV-DON B and WNV-CIP seem more resistances than others 
WNV strains examined, all WNV strains are highly susceptible to antiviral process induced 
by IFN-α action in 1321N1 cells, resulting a more reduction in infectious particle production 
than that observed in Vero cells. The different response of WNV-DON B and WNV-CIP to 
IFN-α action may due to major resistance to the antiviral effects of IFN-α or develop 
different mechanism(s) to counteract the antiviral process induced by IFN-α action.  
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Figure 20. Growth kinetics of WNV strains on 1321N1 cells and susceptibility to IFN-α  
action. 1321N1 cells were pre-treated with 0 (bleu lines) or 100 U/mL IFN-α (red lines) for 
24h prior to WNV infection. Cells were then infected (1 MOI) with WNV-NY99, WNV-
TOS, WNV-AN 1, WNV-DON B, or WNV-CIP for 1,5 hours. Following infection, medium 
containing 0 (bleu lines) or 100 U/mL IFN-α (red lines) was added to cells. At indicated 
times 0, 24, and 48 hours post-infection, cell culture supernatants were harvested and the 
titres of the viruses were determined by TCID50/ml assay on Vero cells. Each growth curve 
experiment was performed in triplicate, and each TCID50 assay was undertaken in duplicate. 
Results are expressed as the mean TCID50/ml ± standard deviation. 
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DISCUSSION 
This study examined the phenotypic and interferon-α (IFN-α)-regulatory properties of 
different WNV lineage 1 and 2 strains that are circulating in Europe/Italy in two cell lines: 
Vero and 1321N1. 
West Nile virus (WNV) is a neurotropic, arthropod-borne flavivirus that is maintained in 
nature in a mosquito-bird cycle, whereas humans and horses are considered incidental or 
“dead-end” hosts. In humans, infection with WNV remains asymptomatic in most of cases, 
about 80%. However, in 20% of cases, WNV causes a mild flu-like illness (West Nile Fever, 
WNF) and less than 1% of clinical cases progress to severe neuroinvasive disease (West Nile 
Neuroinvasive Disease, WNND). Phylogenetic analyses have described two major distinct 
lineages of WNV strains: lineage 1, the largest and most widespread, is found in Africa, 
Asia, the Middle East, Europe, Australia and Americas; and lineage 2 isolates are found 
primarily in sub-Saharan Africa and Madagascar with recent introductions into Europe 
(Greece, Hungary and Italy) and Russia (McMullen AR., et al., 2013). The first human cases 
of WNV infection in Italy were reported in 2008 in Emilia-Romagna region. In the following 
years, WNV circulation was reported in other Italian regions associated with outbreaks of 
meningo-encephalitis caused by different viral strains belonging to distinct lineages. The 
rapid spread of highly pathogenic strains of WNV into naïve populations in Europe, Israel, 
and the USA has resulted in both increased number of human cases and severity of disease 
compared to previous outbreaks. This may suggest that epidemic forms of virus may have 
undergone genetic variations that may affect WNV virulence and/or may encode 
mechanisms to counteract the host immunity. The innate immune system acts as the first line 
of defense against invading viral pathogens and it is critically important for controlling 
infection. WNV infection triggers a delayed host response including the interference with 
type I interferon (IFN) response. IFNs are a family of immuno-modulatory cytokines that are 
produced in response to virus infection and serve as integral signal initiators of host 
intracellular defenses.    
While a large variety of WNV strains from America have been described in terms of genetic, 
phenotypic and pathogenic properties, there are few data about biological characteristics of 
European/Italian WNV isolates highlight the importance to achieve a better knowledge on 
this emerging viral infection. Initially, we examined the biological properties of four WNV 
lineage 1 strains (WNV-NY99, WNV-TOS, WNV-AN 1 and WNV-DON B) and one WNV 
lineage 2 strain (WNV-CIP) circulating in Europe/Italy in Vero cells (African green monkey 
kidney epithelial cells). We found that growth analyses of WNV lineage 1 strains replication 
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in Vero cells display growth kinetics and peak infectious virus production nearly identical to 
WNV strains well-characterized lineage 1 strains isolated in America. These finding are in 
accord with Keller BC., et al., 2006, which found that TX02, a WNV lineage 1 strain 
isolated from the brain of an infected grackle in Texas in 2002 and sharing genotypic traits 
with other American lineage 1 WNV strains, exhibited similar phenotypic growth to that of 
other WNV lineage 1 strain: WNV-NY3356, a strain 99.9% identical to the WNV-NY99. 
However, our data are in contrast with Keller BC., et al., 2006 about results with WNV 
lineage 2 strain. In fact, while Keller BC., et al., 2006 found that growth kinetics of WNV-
MAD78, a nonpathogenic lineage 2 strain, was delayed and peak infectious virus production 
was decreased 10-fold relative to lineage 1 strains; we found that growth analyses of WNV-
CIP replication in Vero cells exhibits a similar replication fitness and biological properties 
nearly identical to those of WNV lineage 1 strains. We hypothesized that the different 
phenotypic properties of WNV-CIP, compared to WNV-MAD78, may be due to their 
different pathogenicity: whereas WNV-MAD78 is an avirulent lineage 2 African isolate with 
no association with human disease, WNV-CIP is a pathogenic lineage 2 strain isolated from 
a patient with neuroinvasive disease.  
Moreover, we investigated if there were differences in the virulence and neuroinvasion 
properties or specific-strain restriction at the blood-brain barrier (BBB) between WNV 
lineage 1 and 2 strains. Several studies have proposed that the severity of WNV infection in 
immunocompetent animals is unrelated to the virus lineage but is highly strain-specific and 
that a determining factor for neuropathogenicity dependents on the capacity of the strain to 
invade the CNS though breakdown of the BBB. Astrocytes and microglia are the principal 
cells within the CNS responsible for initiating, regulating, and maintaining neuroimmune 
response to viral infections. Although WNV is a neurotropic virus, its relative ability to 
replicate in astrocytes is unknown. Thus, we compared the ability of four WNV strains 
belonging to lineage 1 (WNV-NY99, WNV-TOS, WNV-AN 1 and WNV-DON B) and one 
WNV strain belonging to lineage 2 (WNV-CIP) to replicate in human astrocytoma 1321N1 
cells. The results of the present study demonstrated that all WNV strains tested exhibited 
similar growth kinetics and peak infectious virus production in 1321N1 cells, although 
WNV-CIP had a slight delay at early times post-infection compared to those lineage 1 WNV 
strains. In addition, astrocytes supported productive WNV replication in vitro. Our results of 
growth properties with WNV lineage 1 strains are in accord with previous in vitro Cheeran 
MCJ., et al., 2005 and Hussmann KL., et al., 2013 studies which tested the growth 
properties of WNV lineage 1 strains, WNV-NY99 and WNV-NY3356 respectively, in 
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astrocytes where they found that astrocytes supported productive WNV lineage 1 strains 
infection. However, our findings are in contrast with Hussmann KL., et al., 2013 studies 
about growth properties of WNV lineage 2 strains. In fact, whereas we found that WNV-CIP 
shown similar growth kinetics in astrocytes compared to those of WNV lineage 1 strains, 
Hussmann KL., et al., 2013 observed that replication of WNV-MAD78, a WNV lineage 2 
strain, in astrocytes was both delayed and reduced compared to that of WNV lineage 1 
strain, WNV-NY3356. The hypothesis for these discordant results about WNV lineage 2 
strains is due to different pathogenicity of lineage 2 strains used, probably due to evolution 
of this lineage. In fact, WNV-MAD78 used by Hussmann KL., et al., 2013 is an avirulent 
WNV lineage 2 strain isolated from an infected parrot in Madagascar in 1978, whereas in 
this study we used WNV-CIP, a WNV lineage 2 strain isolated from an infected patient with 
neuroinvasive disease in Italy in 2014. Until recently, viruses in lineage 2 were not thought 
to be of public health importance due to few outbreaks of diseases being associated with 
viruses in this lineage. However, recent epidemics of lineage 2 in Europe (Greece and Italy) 
and Russia have shown the increasing importance of this lineage. The McMuller AR., et al., 
2013 study shows that lineage 2 has evolved over the past 300-400 years and appears to 
correlate with a change from mouse attenuated to virulent phenotype based on previous 
studies by their group. Moreover, this evolution mirrors that which is seen in lineage 1 
isolates, which have also evolved to a virulent phenotype over the same period of time 
(McMuller AR., et al., 2013). Thus, WNV-CIP, associates with a recent outbreak in Italy, is 
a WNV lineage 2 strain with a virulent phenotype and it is possible that it has a transmission 
behavior characteristic more similar to pathogenic WNV lineage 1 strains than to that seen in 
avirulent WNV lineage 2 strains. 
IFN-α plays an integral role in intracellular innate immunity as well as in the linkage of the 
innate immune response to cell-mediate defenses against virus infection. In order to replicate 
and spread, viruses direct processes to attenuate the initiation of IFN production and/or to 
antagonize the antiviral actions of IFN inside the host cell. The process by which members 
of the family Flaviviridae regulate host defence and IFN actions vary widely. In order, to 
understand if IFN may influence the growth properties of WNV lineage 1 and 2 strains, we 
compared the susceptibility to interferon-α (IFN-α) action of four WNV strains belonging to 
lineage 1 (WNV-NY99, WNV-TOS, WNV-AN 1 and WNV-DON B) and one WNV strain 
belonging to lineage 2 (WNV-CIP) in Vero and 1321N1 cells. Our results show that both 
WNV lineages 1 and 2 examined exhibit a similar susceptibility to IFN-α action in Vero 
cells resulting in a similar reduction of infectious particle production, suggesting that WNV 
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lineage 2 strain has the same susceptibility to IFN action compared to WNV lineage 1 
strains. Our results are in accord with previous study of Keller BC., et al., 2006, in the same 
experimental conditions. In fact, Keller BC., et al., 2006, to analyze the differential 
responses WNV-MAD78, WNV lineage 2 strain, and WNV-TX02, WNV lineage 1 strain, to 
antiviral effect of IFN, treated cells with IFN founding a similar reduction in infectious 
particle production in both WNV-MAD78 and WNV-TX02. We then evaluated the 
influence of IFN on viral growth in 1321N1 cells. Our results shown that treatment with IFN 
in 1321N1 cells results in an greatly decrease in infectious particle production in both WNV 
lineages 1 and 2, however there is a more reduction in infectious particle production in 
WNV-NY99, WNV-TOS and WNV-AN 1 than in WNV-DON B and WNV-CIP. The 
hypotheses for this different response of WNV-DON B and WNV-CIP to IFN action may 
due to major resistance to the antiviral effects of IFN for some other undefinited 
mechanism(s) that may contribute to control and counteract the antiviral process induced by 
IFN action in 1321N1 cells. However, these results demonstrate that, although WNV-DON 
B and WNV-CIP seem more resistances to IFN action on 1321N1 cells than others WNV 
strains examined, all WNV strains are highly susceptible to antiviral process induced by 
antiviral IFN action in 1321N1 cells, resulting in a more reduction in infectious particle 
production than to that observed in Vero cells. 
While recent works with WNV has focused primarily on lineage 1 and 2 isolates, 
particularly in America (Cheeran MCJ., et al., 2005; Keller BC., et al., 2006; Hussmann 
KL., et al., 2013), there are few experimental studies on biological properties of WNV 
strains isolated in Europe/Italy and on recent WNV lineage 2 pathogenic strains. This is the 
first study that examined the phenotypic properties of WNV strains circulating in 
Europe/Italy including a WNV lineage 2 strain and their susceptibility to IFN action. This 
study contributes to augment our knowledge about WNV strains that are circulating in 
Europe/Italy on their pathogenetic potential in terms of tropism for different cell types and 
susceptibility to antiviral action of IFN. In addition, it provides us new knowledge about 
phenotypic properties of WNV lineage 2 associated with outbreaks of meningoencephalithis 
disease. A better understanding of how European/Italian WNV isolates are evolving can 
provide insights into the future evolution of WNV strains, and allow us to better predict how 
these isolates will lead to future outbreaks and epidemics. Moreover, an augmented 
knowledge on the pathogenesis of this neuroinvasive infection and on virus-host 
interactions, including how WNV control the IFN system, can facilitate the development of 
novel therapeutic approaches.  
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